false --12-31 Q3 0001713210 http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember 0001713210 2025-01-01 2025-09-30 0001713210 2025-11-10 0001713210 2025-09-30 0001713210 2024-12-31 0001713210 us-gaap:NonrelatedPartyMember 2025-09-30 0001713210 us-gaap:NonrelatedPartyMember 2024-12-31 0001713210 us-gaap:RelatedPartyMember 2025-09-30 0001713210 us-gaap:RelatedPartyMember 2024-12-31 0001713210 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-09-30 0001713210 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-12-31 0001713210 2025-07-01 2025-09-30 0001713210 2024-07-01 2024-09-30 0001713210 2024-01-01 2024-09-30 0001713210 us-gaap:CommonStockMember 2023-12-31 0001713210 us-gaap:TreasuryStockCommonMember 2023-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001713210 us-gaap:RetainedEarningsMember 2023-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2023-12-31 0001713210 2023-12-31 0001713210 us-gaap:CommonStockMember 2024-03-31 0001713210 us-gaap:TreasuryStockCommonMember 2024-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001713210 us-gaap:RetainedEarningsMember 2024-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2024-03-31 0001713210 2024-03-31 0001713210 us-gaap:CommonStockMember 2024-06-30 0001713210 us-gaap:TreasuryStockCommonMember 2024-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001713210 us-gaap:RetainedEarningsMember 2024-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2024-06-30 0001713210 2024-06-30 0001713210 us-gaap:CommonStockMember 2024-12-31 0001713210 us-gaap:TreasuryStockCommonMember 2024-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001713210 us-gaap:RetainedEarningsMember 2024-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2024-12-31 0001713210 us-gaap:CommonStockMember 2025-03-31 0001713210 us-gaap:TreasuryStockCommonMember 2025-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001713210 us-gaap:RetainedEarningsMember 2025-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2025-03-31 0001713210 2025-03-31 0001713210 us-gaap:CommonStockMember 2025-06-30 0001713210 us-gaap:TreasuryStockCommonMember 2025-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001713210 us-gaap:RetainedEarningsMember 2025-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2025-06-30 0001713210 2025-06-30 0001713210 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001713210 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001713210 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001713210 2024-01-01 2024-03-31 0001713210 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001713210 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001713210 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001713210 2024-04-01 2024-06-30 0001713210 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001713210 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001713210 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001713210 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001713210 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001713210 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001713210 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001713210 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001713210 2025-01-01 2025-03-31 0001713210 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001713210 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001713210 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001713210 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001713210 2025-04-01 2025-06-30 0001713210 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001713210 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001713210 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001713210 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001713210 us-gaap:CommonStockMember 2024-09-30 0001713210 us-gaap:TreasuryStockCommonMember 2024-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001713210 us-gaap:RetainedEarningsMember 2024-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001713210 us-gaap:NoncontrollingInterestMember 2024-09-30 0001713210 2024-09-30 0001713210 us-gaap:CommonStockMember 2025-09-30 0001713210 us-gaap:TreasuryStockCommonMember 2025-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001713210 us-gaap:RetainedEarningsMember 2025-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001713210 us-gaap:NoncontrollingInterestMember 2025-09-30 0001713210 ATPC:AgapeATPCorporationLabuanMember 2025-09-30 0001713210 ATPC:ShareExchangeAgreementMember ATPC:MrHowKokChoongMember 2020-05-07 2020-05-08 0001713210 ATPC:AgapeSuperiorLivingSdnBhdMember 2020-05-08 0001713210 2024-11-25 0001713210 ATPC:DSYWellnessInternationalSdnBhdMember 2021-11-11 0001713210 ATPC:OIEATPCHoldingsMSdnBhdMember 2024-01-03 0001713210 ATPC:OIEATPCHoldingsMSdnBhdMember 2024-03-14 0001713210 2024-09-19 0001713210 ATPC:AgapeATPCorporationLabuanMember 2025-01-01 2025-09-30 0001713210 ATPC:AgapeATPInternationalHoldingLimitedMember 2025-01-01 2025-09-30 0001713210 ATPC:AgapeATPInternationalHoldingLimitedMember 2025-09-30 0001713210 ATPC:AgapeSuperiorLivingSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:AgapeSuperiorLivingSdnBhdMember 2025-09-30 0001713210 ATPC:AgapeSEASdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:CedarATPCSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:CedarATPCSdnBhdMember 2025-09-30 0001713210 ATPC:DSYWellnessInternationalSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:DSYWellnessInternationalSdnBhdMember 2025-09-30 0001713210 ATPC:ATPCGreenEnergySdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:ATPCGreenEnergySdnBhdMember 2025-09-30 0001713210 ATPC:OIEATPCEximMSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:OIEATPCEximMSdnBhdMember 2025-09-30 0001713210 ATPC:ATPCTechnologyPrivateLimitedMember 2025-01-01 2025-09-30 0001713210 ATPC:ATPCTechnologyPrivateLimitedMember 2025-09-30 0001713210 ATPC:HealthAndWellnessServicesMember 2025-01-01 2025-09-30 0001713210 ATPC:ProductHealthTherapiesMember 2025-07-01 2025-09-30 0001713210 ATPC:ProductHealthTherapiesMember 2024-07-01 2024-09-30 0001713210 ATPC:ProductHealthTherapiesMember 2025-01-01 2025-09-30 0001713210 ATPC:ProductHealthTherapiesMember 2024-01-01 2024-09-30 0001713210 ATPC:HealthAndWellnessServicesMember 2025-07-01 2025-09-30 0001713210 ATPC:HealthAndWellnessServicesMember 2024-07-01 2024-09-30 0001713210 ATPC:HealthAndWellnessServicesMember 2024-01-01 2024-09-30 0001713210 ATPC:GreenEnergyMember 2025-07-01 2025-09-30 0001713210 ATPC:GreenEnergyMember 2024-07-01 2024-09-30 0001713210 ATPC:GreenEnergyMember 2025-01-01 2025-09-30 0001713210 ATPC:GreenEnergyMember 2024-01-01 2024-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2025-07-01 2025-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2024-07-01 2024-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2025-01-01 2025-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2024-01-01 2024-09-30 0001713210 ATPC:SocialSecurityOrganizationMember 2025-01-01 2025-09-30 0001713210 ATPC:EmployeesProvidentFundMember srt:MinimumMember 2025-01-01 2025-09-30 0001713210 ATPC:EmployeesProvidentFundMember srt:MaximumMember 2025-01-01 2025-09-30 0001713210 ATPC:EmploymentInsuranceSystemMember 2025-01-01 2025-09-30 0001713210 ATPC:HumanResourceDevelopmentFundMember 2025-01-01 2025-09-30 0001713210 ATPC:ComputerAndOfficeEquipmentMember srt:MinimumMember 2025-09-30 0001713210 ATPC:ComputerAndOfficeEquipmentMember srt:MaximumMember 2025-09-30 0001713210 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2025-09-30 0001713210 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2025-09-30 0001713210 us-gaap:VehiclesMember 2025-09-30 0001713210 us-gaap:LeaseholdImprovementsMember 2025-09-30 0001713210 us-gaap:ComputerSoftwareIntangibleAssetMember 2025-09-30 0001713210 ATPC:EnergizedMineralConcentrateMember 2025-07-01 2025-09-30 0001713210 ATPC:EnergizedMineralConcentrateMember 2024-07-01 2024-09-30 0001713210 ATPC:EnergizedMineralConcentrateMember 2025-01-01 2025-09-30 0001713210 ATPC:EnergizedMineralConcentrateMember 2024-01-01 2024-09-30 0001713210 ATPC:IonizedCalMagMember 2025-07-01 2025-09-30 0001713210 ATPC:IonizedCalMagMember 2024-07-01 2024-09-30 0001713210 ATPC:IonizedCalMagMember 2025-01-01 2025-09-30 0001713210 ATPC:IonizedCalMagMember 2024-01-01 2024-09-30 0001713210 ATPC:LIVO5Member 2025-07-01 2025-09-30 0001713210 ATPC:LIVO5Member 2024-07-01 2024-09-30 0001713210 ATPC:LIVO5Member 2025-01-01 2025-09-30 0001713210 ATPC:LIVO5Member 2024-01-01 2024-09-30 0001713210 ATPC:SoyProteinIsolatePowderMember 2025-07-01 2025-09-30 0001713210 ATPC:SoyProteinIsolatePowderMember 2024-07-01 2024-09-30 0001713210 ATPC:SoyProteinIsolatePowderMember 2025-01-01 2025-09-30 0001713210 ATPC:SoyProteinIsolatePowderMember 2024-01-01 2024-09-30 0001713210 ATPC:MixSoyProteinIsolatePowderWithBlackSesameMember 2025-07-01 2025-09-30 0001713210 ATPC:MixSoyProteinIsolatePowderWithBlackSesameMember 2024-07-01 2024-09-30 0001713210 ATPC:MixSoyProteinIsolatePowderWithBlackSesameMember 2025-01-01 2025-09-30 0001713210 ATPC:MixSoyProteinIsolatePowderWithBlackSesameMember 2024-01-01 2024-09-30 0001713210 ATPC:SkinCareAndHealthCareProductsMember 2025-07-01 2025-09-30 0001713210 ATPC:SkinCareAndHealthCareProductsMember 2024-07-01 2024-09-30 0001713210 ATPC:SkinCareAndHealthCareProductsMember 2025-01-01 2025-09-30 0001713210 ATPC:SkinCareAndHealthCareProductsMember 2024-01-01 2024-09-30 0001713210 us-gaap:ProductMember 2025-07-01 2025-09-30 0001713210 us-gaap:ProductMember 2024-07-01 2024-09-30 0001713210 us-gaap:ProductMember 2025-01-01 2025-09-30 0001713210 us-gaap:ProductMember 2024-01-01 2024-09-30 0001713210 ATPC:PeriodEndMYRMember 2025-09-30 0001713210 ATPC:PeriodEndMYRMember 2024-12-31 0001713210 ATPC:PeriodEndHKDMember 2025-09-30 0001713210 ATPC:PeriodEndHKDMember 2024-12-31 0001713210 ATPC:PeriodEndCNYMember 2025-09-30 0001713210 ATPC:PeriodEndCNYMember 2024-12-31 0001713210 ATPC:PeriodAverageMYRMember 2025-07-01 2025-09-30 0001713210 ATPC:PeriodAverageMYRMember 2024-07-01 2024-09-30 0001713210 ATPC:PeriodAverageMYRMember 2025-01-01 2025-09-30 0001713210 ATPC:PeriodAverageMYRMember 2024-01-01 2024-09-30 0001713210 ATPC:PeriodAverageHKDMember 2025-07-01 2025-09-30 0001713210 ATPC:PeriodAverageHKDMember 2024-07-01 2024-09-30 0001713210 ATPC:PeriodAverageHKDMember 2025-01-01 2025-09-30 0001713210 ATPC:PeriodAverageHKDMember 2024-01-01 2024-09-30 0001713210 ATPC:PeriodAverageCNYMember 2025-07-01 2025-09-30 0001713210 ATPC:PeriodAverageCNYMember 2024-07-01 2024-09-30 0001713210 ATPC:PeriodAverageCNYMember 2025-01-01 2025-09-30 0001713210 ATPC:PeriodAverageCNYMember 2024-01-01 2024-09-30 0001713210 ATPC:AgapeSuperiorLivingSdnBhdMember ATPC:AgapeSEASdnBhdMember 2025-09-30 0001713210 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-07-01 2025-09-30 0001713210 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-07-01 2024-09-30 0001713210 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-01-01 2025-09-30 0001713210 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-01-01 2024-09-30 0001713210 srt:MinimumMember 2024-09-30 0001713210 srt:MaximumMember 2024-09-30 0001713210 2024-01-01 2024-12-31 0001713210 ATPC:ComputerAndOfficeEquipmentMember 2025-09-30 0001713210 ATPC:ComputerAndOfficeEquipmentMember 2024-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2025-09-30 0001713210 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001713210 us-gaap:VehiclesMember 2024-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001713210 ATPC:GreenproCapitalCorpMember 2018-05-17 2018-05-17 0001713210 ATPC:GreenproCapitalCorpMember 2018-05-17 0001713210 ATPC:GreenproCapitalCorpMember 2018-07-30 0001713210 ATPC:GreenproCapitalCorpMember 2018-07-30 2018-07-30 0001713210 ATPC:GreenproCapitalCorpMember 2018-10-16 2018-10-16 0001713210 ATPC:GreenproCapitalCorpMember 2018-10-16 0001713210 ATPC:GreenproCapitalCorpMember 2022-07-18 2022-07-19 0001713210 ATPC:GreenproCapitalCorpMember 2022-07-28 0001713210 ATPC:GreenproCapitalCorpMember 2022-07-19 0001713210 ATPC:DSwissIncMember 2020-11-03 2020-11-03 0001713210 ATPC:DSwissIncMember 2020-11-03 0001713210 ATPC:DSwissIncMember 2020-12-09 2020-12-09 0001713210 ATPC:DSwissIncMember 2020-12-09 0001713210 ATPC:SEATechVenturesCorpMember 2021-09-27 2021-09-27 0001713210 ATPC:SEATechVenturesCorpMember 2021-09-27 0001713210 ATPC:PhoenixPlusCorpMember 2019-04-03 2019-04-03 0001713210 ATPC:PhoenixPlusCorpMember 2019-04-03 0001713210 ATPC:PhoenixPlusCorpMember srt:MinimumMember 2022-05-18 2024-07-16 0001713210 ATPC:PhoenixPlusCorpMember srt:MaximumMember 2022-05-18 2024-07-16 0001713210 ATPC:RadianceHoldingsCorpMember 2024-07-02 2024-07-02 0001713210 ATPC:RadianceHoldingsCorpMember 2024-07-02 0001713210 ATPC:PhoenixPlusCorpMember 2024-07-02 2024-07-02 0001713210 ATPC:PhoenixPlusCorpMember 2025-09-30 0001713210 ATPC:PhoenixPlusCorpMember 2024-12-31 0001713210 srt:MaximumMember 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdMember 2024-01-01 2024-12-31 0001713210 ATPC:TH3TechnologySdnBhdMember 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdMember 2024-12-31 0001713210 ATPC:ATPCLegaGlobalSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:ATPCLegaGlobalSdnBhdMember 2024-01-01 2024-12-31 0001713210 ATPC:ATPCLegaGlobalSdnBhdMember 2025-09-30 0001713210 ATPC:ATPCLegaGlobalSdnBhdMember 2024-12-31 0001713210 ATPC:CTANutriceuticalsSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:CTANutriceuticalsSdnBhdMember 2024-01-01 2024-12-31 0001713210 ATPC:CTANutriceuticalsSdnBhdMember 2025-09-30 0001713210 ATPC:CTANutriceuticalsSdnBhdMember 2024-12-31 0001713210 ATPC:SYWelltechSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:SYWelltechSdnBhdMember 2024-01-01 2024-12-31 0001713210 ATPC:SYWelltechSdnBhdMember 2025-09-30 0001713210 ATPC:SYWelltechSdnBhdMember 2024-12-31 0001713210 ATPC:CedarWellnessSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdMember 2024-01-01 2024-12-31 0001713210 ATPC:CedarWellnessSdnBhdMember 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdMember 2024-12-31 0001713210 ATPC:ICTMMember 2025-01-01 2025-09-30 0001713210 ATPC:ICTMMember 2024-01-01 2024-12-31 0001713210 ATPC:ICTMMember 2025-09-30 0001713210 ATPC:ICTMMember 2024-12-31 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdMember 2024-01-01 2024-12-31 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdMember 2025-09-30 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdMember 2024-12-31 0001713210 ATPC:CedarWellnessSdnBhdOneMember 2025-01-01 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdOneMember 2024-01-01 2024-12-31 0001713210 ATPC:CedarWellnessSdnBhdOneMember 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdOneMember 2024-12-31 0001713210 ATPC:LowMuiChinMember 2025-01-01 2025-09-30 0001713210 ATPC:LowMuiChinMember 2024-01-01 2024-12-31 0001713210 ATPC:LowMuiChinMember 2025-09-30 0001713210 ATPC:LowMuiChinMember 2024-12-31 0001713210 ATPC:HowKokChoongMember 2025-01-01 2025-09-30 0001713210 ATPC:HowKokChoongMember 2024-01-01 2024-12-31 0001713210 ATPC:HowKokChoongMember 2025-09-30 0001713210 ATPC:HowKokChoongMember 2024-12-31 0001713210 ATPC:CTANutriceuticalsSdnBhdOneMember 2025-07-01 2025-09-30 0001713210 ATPC:CTANutriceuticalsSdnBhdOneMember 2024-07-01 2024-09-30 0001713210 ATPC:DSYBeautySdnBhdTwoMember 2025-07-01 2025-09-30 0001713210 ATPC:DSYBeautySdnBhdTwoMember 2024-07-01 2024-09-30 0001713210 ATPC:ICTMMember 2025-07-01 2025-09-30 0001713210 ATPC:ICTMMember 2024-07-01 2024-09-30 0001713210 ATPC:CedarWellnessSdnBhdMember 2025-07-01 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdMember 2024-07-01 2024-09-30 0001713210 us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0001713210 us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0001713210 ATPC:CTANutriceuticalsSdnBhdOneMember 2025-01-01 2025-09-30 0001713210 ATPC:CTANutriceuticalsSdnBhdOneMember 2024-01-01 2024-09-30 0001713210 ATPC:DSYBeautySdnBhdTwoMember 2025-01-01 2025-09-30 0001713210 ATPC:DSYBeautySdnBhdTwoMember 2024-01-01 2024-09-30 0001713210 ATPC:ICTMMember 2024-01-01 2024-09-30 0001713210 ATPC:CedarWellnessSdnBhdMember 2024-01-01 2024-09-30 0001713210 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0001713210 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdOneMember 2025-07-01 2025-09-30 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdOneMember 2024-07-01 2024-09-30 0001713210 ATPC:DSYBeautySdnBhdThreeMember 2025-07-01 2025-09-30 0001713210 ATPC:DSYBeautySdnBhdThreeMember 2024-07-01 2024-09-30 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdOneMember 2025-01-01 2025-09-30 0001713210 ATPC:CTANutriceuticalsAsiaSdnBhdOneMember 2024-01-01 2024-09-30 0001713210 ATPC:DSYBeautySdnBhdThreeMember 2025-01-01 2025-09-30 0001713210 ATPC:DSYBeautySdnBhdThreeMember 2024-01-01 2024-09-30 0001713210 ATPC:HowKokChoongOneMember 2025-07-01 2025-09-30 0001713210 ATPC:HowKokChoongOneMember 2024-07-01 2024-09-30 0001713210 ATPC:HowKokChoongOneMember 2025-01-01 2025-09-30 0001713210 ATPC:HowKokChoongOneMember 2024-01-01 2024-09-30 0001713210 ATPC:AndoDesignSdnBhdMember 2025-07-01 2025-09-30 0001713210 ATPC:AndoDesignSdnBhdMember 2024-07-01 2024-09-30 0001713210 ATPC:TH3TechnologySdnBhdOneMember 2025-07-01 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdOneMember 2024-07-01 2024-09-30 0001713210 ATPC:AndoDesignSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:AndoDesignSdnBhdMember 2024-01-01 2024-09-30 0001713210 ATPC:TH3TechnologySdnBhdOneMember 2025-01-01 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdOneMember 2024-01-01 2024-09-30 0001713210 ATPC:TH3TechnologySdnBhdTwoMember 2025-07-01 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdTwoMember 2024-07-01 2024-09-30 0001713210 ATPC:DSYWellnessandLongevityCenterSdnBhdThreeMember 2025-07-01 2025-09-30 0001713210 ATPC:DSYWellnessandLongevityCenterSdnBhdThreeMember 2024-07-01 2024-09-30 0001713210 ATPC:CedarWellnessSdnBhdTwoMember 2025-07-01 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdTwoMember 2024-07-01 2024-09-30 0001713210 ATPC:TH3TechnologySdnBhdTwoMember 2025-01-01 2025-09-30 0001713210 ATPC:TH3TechnologySdnBhdTwoMember 2024-01-01 2024-09-30 0001713210 ATPC:SYWelltechSdnBhdWelltechMember 2025-01-01 2025-09-30 0001713210 ATPC:SYWelltechSdnBhdWelltechMember 2024-01-01 2024-09-30 0001713210 ATPC:DSYWellnessandLongevityCenterSdnBhdThreeMember 2025-01-01 2025-09-30 0001713210 ATPC:DSYWellnessandLongevityCenterSdnBhdThreeMember 2024-01-01 2024-09-30 0001713210 ATPC:AndoDesignSdnBhdOneMember 2025-01-01 2025-09-30 0001713210 ATPC:AndoDesignSdnBhdOneMember 2024-01-01 2024-09-30 0001713210 ATPC:CedarWellnessSdnBhdTwoMember 2025-01-01 2025-09-30 0001713210 ATPC:CedarWellnessSdnBhdTwoMember 2024-01-01 2024-09-30 0001713210 2025-02-27 0001713210 2025-03-20 0001713210 2025-03-20 2025-03-20 0001713210 ATPC:ExecutiveDirectorMember 2025-01-01 2025-09-30 0001713210 ATPC:ExecutiveDirectorMember 2024-01-01 2024-12-31 0001713210 us-gaap:CommonStockMember 2023-10-10 2023-10-10 0001713210 us-gaap:CommonStockMember 2023-10-10 0001713210 us-gaap:CommonStockMember 2023-10-13 0001713210 2023-10-13 2023-10-13 0001713210 us-gaap:WarrantMember 2023-10-13 2023-10-13 0001713210 country:US 2025-07-01 2025-09-30 0001713210 country:US 2024-07-01 2024-09-30 0001713210 country:US 2025-01-01 2025-09-30 0001713210 country:US 2024-01-01 2024-09-30 0001713210 country:MY 2025-07-01 2025-09-30 0001713210 country:MY 2024-07-01 2024-09-30 0001713210 country:MY 2025-01-01 2025-09-30 0001713210 country:MY 2024-01-01 2024-09-30 0001713210 country:CN 2025-07-01 2025-09-30 0001713210 country:CN 2024-07-01 2024-09-30 0001713210 country:CN 2025-01-01 2025-09-30 0001713210 country:CN 2024-01-01 2024-09-30 0001713210 country:HK 2025-07-01 2025-09-30 0001713210 country:HK 2024-07-01 2024-09-30 0001713210 country:HK 2025-01-01 2025-09-30 0001713210 country:HK 2024-01-01 2024-09-30 0001713210 us-gaap:StateAndLocalJurisdictionMember 2025-01-01 2025-09-30 0001713210 us-gaap:ForeignCountryMember 2025-01-01 2025-09-30 0001713210 country:US 2025-09-30 0001713210 country:US 2024-12-31 0001713210 country:MY ATPC:SubsequentRMMember 2025-01-01 2025-09-30 0001713210 country:MY ATPC:SubsequentRMMember 2024-01-01 2024-09-30 0001713210 country:MY ATPC:RemainingMember 2025-01-01 2025-09-30 0001713210 country:MY ATPC:RemainingMember 2024-01-01 2024-09-30 0001713210 country:MY 2025-09-30 0001713210 country:MY 2024-12-31 0001713210 ATPC:TwoThousandThirtyOneMember 2025-09-30 0001713210 ATPC:TwoThousandThirtyTwoMember 2025-09-30 0001713210 ATPC:TwoThousandThirtyThreeMember 2025-09-30 0001713210 ATPC:TwoThousandThirtyFourMember 2025-09-30 0001713210 ATPC:TwoThousandThirtyFiveMember 2025-09-30 0001713210 ATPC:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001713210 ATPC:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001713210 ATPC:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember ATPC:OneCompanyMember 2025-01-01 2025-09-30 0001713210 ATPC:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001713210 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ATPC:OneCompanyMember 2025-01-01 2025-09-30 0001713210 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ATPC:OneCompanyMember 2024-01-01 2024-12-31 0001713210 ATPC:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-07-01 2025-09-30 0001713210 ATPC:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-07-01 2025-09-30 0001713210 ATPC:VendorThreeMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-07-01 2025-09-30 0001713210 ATPC:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-07-01 2024-09-30 0001713210 ATPC:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-07-01 2024-09-30 0001713210 ATPC:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorThreeMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-09-30 0001713210 ATPC:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-09-30 0001713210 ATPC:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember ATPC:CTANutriceuticalsSdnBhdMember 2025-07-01 2025-09-30 0001713210 ATPC:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember ATPC:CTANutriceuticalsSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember ATPC:CTANutriceuticalsSdnBhdMember 2024-07-01 2024-09-30 0001713210 ATPC:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember ATPC:CTANutriceuticalsSdnBhdMember 2024-01-01 2024-09-30 0001713210 ATPC:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-12-31 0001713210 ATPC:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-12-31 0001713210 ATPC:VendorThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-12-31 0001713210 ATPC:VendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember ATPC:CTANutriceuticalsSdnBhdMember 2025-01-01 2025-09-30 0001713210 ATPC:VendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember ATPC:CTANutriceuticalsSdnBhdMember 2024-01-01 2024-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember ATPC:OneSalesDistributorMember 2025-07-01 2025-09-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember ATPC:NoSalesDistributorMember 2024-07-01 2024-09-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember ATPC:OneSalesDistributorMember 2025-01-01 2025-09-30 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember ATPC:OneSalesDistributorMember 2024-01-01 2024-09-30 0001713210 2024-07-11 0001713210 ATPC:SkinCareHealthAndWellnessSegmentMember 2025-07-01 2025-09-30 0001713210 ATPC:GreenEnergySegmentMember 2025-07-01 2025-09-30 0001713210 ATPC:UnallocatedExpensesSegmentMember 2025-07-01 2025-09-30 0001713210 ATPC:SkinCareHealthAndWellnessSegmentMember 2025-09-30 0001713210 ATPC:GreenEnergySegmentMember 2025-09-30 0001713210 ATPC:UnallocatedExpensesSegmentMember 2025-09-30 0001713210 ATPC:SkinCareHealthAndWellnessSegmentMember 2024-07-01 2024-09-30 0001713210 ATPC:GreenEnergySegmentMember 2024-07-01 2024-09-30 0001713210 ATPC:UnallocatedExpensesSegmentMember 2024-07-01 2024-09-30 0001713210 ATPC:SkinCareHealthAndWellnessSegmentMember 2024-09-30 0001713210 ATPC:GreenEnergySegmentMember 2024-09-30 0001713210 ATPC:UnallocatedExpensesSegmentMember 2024-09-30 0001713210 ATPC:SkinCareHealthAndWellnessSegmentMember 2025-01-01 2025-09-30 0001713210 ATPC:GreenEnergySegmentMember 2025-01-01 2025-09-30 0001713210 ATPC:UnallocatedExpensesSegmentMember 2025-01-01 2025-09-30 0001713210 ATPC:SkinCareHealthAndWellnessSegmentMember 2024-01-01 2024-09-30 0001713210 ATPC:GreenEnergySegmentMember 2024-01-01 2024-09-30 0001713210 ATPC:UnallocatedExpensesSegmentMember 2024-01-01 2024-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares iso4217:MYR iso4217:CNY iso4217:MYR xbrli:shares xbrli:pure ATPC:Integer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended September 30, 2025

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission File Number 001-41835

AGAPE ATP CORPORATION

(Exact name of registrant issuer as specified in its charter)

Nevada |  | 36-4838886
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1705 - 1708, Level 17, Tower 2, Faber Tower, Jalan Desa Bahagia,

Taman Desa, 58100 Kuala Lumpur, Malaysia. N8

(Address of principal executive offices, including zip code)

Registrant’s phone number, including area code (60) 192230099

Securities registered pursuant to Section 12(b) of the Securities Exchange Act:

Common Stock, $0.0001 par value

(Title of Class)

Nasdaq Capital Market

(Name of exchange on which registered)

ATPC

(Ticker Symbol)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes ☐ No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class |  | Outstanding at November 10, 2025
Common Stock, $0.0001 par value |  | 50,027,000

TABLE OF CONTENTS

|  | Page
PART I | FINANCIAL INFORMATION |
ITEM 1. | UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: |
| Unaudited Condensed Consolidated Balance Sheets | F-1
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss | F-2
| Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity | F-3
| Unaudited Condensed Consolidated Statements of Cash Flows | F-4
| Notes to Unaudited Condensed Consolidated Financial Statements | F-5 - F-38
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 3
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 12
ITEM 4. | CONTROLS AND PROCEDURES | 12
PART II | OTHER INFORMATION |
ITEM 1 | LEGAL PROCEEDINGS | 14
ITEM 2 | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 14
ITEM 3 | DEFAULTS UPON SENIOR SECURITIES | 14
ITEM 4 | MINE SAFETY DISCLOSURES | 14
ITEM 5 | OTHER INFORMATION | 14
ITEM 6 | EXHIBITS | 14
| SIGNATURES | 15

2

PART I FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

|  | September 30, 2025 (Unaudited) |  |  | December 31, 2024 (Audited) |
|  | As of |
|  | September 30, 2025 (Unaudited) |  |  | December 31, 2024 (Audited) |
ASSETS |  |  |  |  |  |  |  |
CURRENT ASSETS |  |  |  |  |  |  |  |
Cash and cash equivalents (Included $307 and $1,139 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2025 and December 31, 2024, respectively.) |  | $ | 133,714 |  |  | $ | 2,040,243 |
Accounts receivable, net |  |  | 7,437 |  |  |  | 53,651 |
Other receivable |  |  | 28 |  |  |  | 2,544 |
Amount due from related parties |  |  | 2,279 |  |  |  | 2,312 |
Other Receivable |  |  | 2,279 |  |  |  | 2,312 |
Inventories |  |  | 39,886 |  |  |  | 46,347 |
Prepaid taxes |  |  | 52,006 |  |  |  | 45,426 |
Prepayments and deposits, net (Included $0 and $7 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2025 and December 31, 2024, respectively.) |  |  | 23,834,956 |  |  |  | 586,172 |
Total Current Assets |  |  | 24,070,306 |  |  |  | 2,776,695 |
NON-CURRENT ASSETS |  |  |  |  |  |  |  |
Property and equipment, net |  |  | 15,122 |  |  |  | 31,463 |
Intangible assets, net |  |  | 10,289 |  |  |  | 13,082 |
Finance lease assets |  |  | 156,228 |  |  |  | 178,948 |
Operating right-of-use assets |  |  | 119,021 |  |  |  | 224,595 |
Investment in marketable securities |  |  | 16,878 |  |  |  | 13,737 |
Investment in non-marketable securities |  |  | 1,500 |  |  |  | 1,500 |
Total Non-Current Assets |  |  | 319,038 |  |  |  | 463,325 |
TOTAL ASSETS |  | $ | 24,389,344 |  |  | $ | 3,240,020 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
CURRENT LIABILITIES |  |  |  |  |  |  |  |
Accounts payable |  |  | 85,145 |  |  |  | 102,798 |
Accounts payable – related parties |  |  | 35,064 |  |  |  | 30,625 |
Accounts payable |  |  | 35,064 |  |  |  | 30,625 |
Customer deposits |  |  | 98,504 |  |  |  | 96,976 |
Operating lease liabilities, current |  |  | 119,657 |  |  |  | 150,370 |
Other payables and accrued liabilities ($1,282 and $1,478 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of September 30, 2025 and December 31, 2024, respectively.) |  |  | 600,103 |  |  |  | 712,436 |
Other payable – related parties |  |  | 522,795 |  |  |  | 850 |
Finance lease liabilities, current |  |  | 23,991 |  |  |  | 21,635 |
Income tax payable |  |  | - |  |  |  | 4,434 |
Total Current Liabilities |  |  | 1,485,259 |  |  |  | 1,120,124 |
NON-CURRENT LIABILITIES |  |  |  |  |  |  |  |
Operating lease liabilities, non-current |  |  | - |  |  |  | 75,425 |
Finance lease liabilities, non-current |  |  | 104,159 |  |  |  | 115,350 |
Total Non-Current Liabilities |  |  | 104,159 |  |  |  | 190,775 |
TOTAL LIABILITIES |  | $ | 1,589,418 |  |  | $ | 1,310,899 |
COMMITMENTS AND CONTINGENCIES (Note 20) |  |  | - |  |  |  | - |
STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; Nil issued and outstanding |  |  | - |  |  |  | - |
Common Stock, par value $0.0001; 500,000,000 shares authorized, 50,005,381 and 3,989,056 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. |  |  | 5,001 |  |  |  | 399 |
Additional paid in capital |  |  | 34,237,074 |  |  |  | 11,422,708 |
Accumulated deficit |  |  | (11,420,899 | ) |  |  | (9,518,045 | )
Accumulated other comprehensive income |  |  | 12,074 |  |  |  | 27,852 |
TOTAL AGAPE ATP CORPORATION STOCKHOLDERS’ EQUITY |  |  | 22,833,250 |  |  |  | 1,932,914 |
NON-CONTROLLING INTERESTS |  |  | (33,324 | ) |  |  | (3,793 | )
TOTAL EQUITY |  |  | 22,799,926 |  |  |  | 1,929,121 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |  | $ | 24,389,344 |  |  | $ | 3,240,020 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-1

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | For the three months ended |  |  | For the nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
REVENUE |  | $ | 370,593 |  |  | $ | 331,289 |  |  | $ | 1,125,129 |  |  | $ | 962,971 |
COST OF REVENUE |  |  | (131,490 | ) |  |  | (147,104 | ) |  |  | (520,800 | ) |  |  | (381,805 | )
GROSS PROFIT |  |  | 239,103 |  |  |  | 184,185 |  |  |  | 604,329 |  |  |  | 581,166 |
SELLING |  |  | (61,623 | ) |  |  | (41,582 | ) |  |  | (187,214 | ) |  |  | (129,938 | )
COMMISSION |  |  | (27,386 | ) |  |  | (6,894 | ) |  |  | (51,350 | ) |  |  | (23,573 | )
GENERAL AND ADMINISTRATIVE |  |  | (751,415 | ) |  |  | (683,819 | ) |  |  | (2,324,451 | ) |  |  | (2,152,889 | )
TOTAL OPERATING EXPENSES |  |  | (840,424 | ) |  |  | (732,295 | ) |  |  | (2,563,015 | ) |  |  | (2,306,400 | )
LOSS FROM OPERATIONS |  |  | (601,321 | ) |  |  | (548,110 | ) |  |  | (1,958,686 | ) |  |  | (1,725,234 | )
OTHER INCOME |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other income, net |  |  | 2,774 |  |  |  | 3,445 |  |  |  | 14,776 |  |  |  | 25,942 |
Interest income |  |  | - |  |  |  | 16,291 |  |  |  | 3,416 |  |  |  | 58,432 |
Unrealized holding (loss) gain on marketable securities |  |  | (3,487 | ) |  |  | (1,176 | ) |  |  | 3,165 |  |  |  | (6,642 | )
Gain on disposal of property and equipment |  |  | - |  |  |  | 111 |  |  |  | - |  |  |  | 111 |
Exchange gain, net |  |  | 7,860 |  |  |  | 2,525 |  |  |  | 6,990 |  |  |  | 1,745 |
TOTAL OTHER INCOME, NET |  |  | 7,147 |  |  |  | 21,196 |  |  |  | 28,347 |  |  |  | 79,588 |
LOSS BEFORE INCOME TAXES |  |  | (594,174 | ) |  |  | (526,914 | ) |  |  | (1,930,339 | ) |  |  | (1,645,646 | )
INCOME TAX (EXPENSE) CREDIT |  |  | (1,196 | ) |  |  | 2,875 |  |  |  | (1,196 | ) |  |  | (13,803 | )
NET LOSS |  |  | (595,370 | ) |  |  | (524,039 | ) |  |  | (1,931,535 | ) |  |  | (1,659,449 | )
LESS: NET (LOSS) INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS |  |  | (8,543 | ) |  |  | (14,411 | ) |  |  | (28,681 | ) |  |  | 2,586 |
NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION |  | $ | (586,827 | ) |  | $ | (509,628 | ) |  | $ | (1,902,854 | ) |  | $ | (1,662,035 | )
NET LOSS |  | $ | (595,370 | ) |  | $ | (524,039 | ) |  | $ | (1,931,535 | ) |  | $ | (1,659,449 | )
OTHER COMPREHENSIVE (LOSS) INCOME |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  |  | (11,175 | ) |  |  | 7,224 |  |  |  | (15,778 | ) |  |  | 3,896 |
TOTAL COMPREHENSIVE LOSS |  |  | (606,545 | ) |  |  | (516,815 | ) |  |  | (1,947,313 | ) |  |  | (1,655,553 | )
Less: Comprehensive (loss) income attributable to non-controlling interests |  |  | (8,620 | ) |  |  | (12,522 | ) |  |  | (29,531 | ) |  |  | 4,233 |
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION |  | $ | (597,925 | ) |  | $ | (504,293 | ) |  | $ | (1,917,782 | ) |  | $ | (1,659,786 | )
LOSS PER SHARE |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic and diluted |  | $ | (0.01 | ) |  | $ | (0.13 | ) |  | $ | (0.05 | ) |  | $ | (0.43 | )
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic and diluted |  |  | 50,005,381 |  |  |  | 3,881,074 |  |  |  | 36,691,872 |  |  |  | 3,859,393 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-2

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF

CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

|  | Number of shares |  |  | Par value |  |  | Number of shares |  |  | Par value |  |  | PAID IN CAPITAL |  |  | ACCUMULATED DEFICIT |  |  | COMPREHENSIVE INCOME |  |  | CONTROLLING INTERESTS |  |  | STOCKHOLDERS’ EQUITY |
|  | COMMON STOCK |  |  | TREASURY STOCK |  |  | ADDITIONAL |  |  |  |  |  | ACCUMULATED OTHER |  |  | NON- |  |  | TOTAL |
|  | Number of shares |  |  | Par value |  |  | Number of shares |  |  | Par value |  |  | PAID IN CAPITAL |  |  | ACCUMULATED DEFICIT |  |  | COMPREHENSIVE INCOME |  |  | CONTROLLING INTERESTS |  |  | STOCKHOLDERS’ EQUITY |
Balance as of December 31, 2023 |  |  | 3,855,126 |  |  | $ | 386 |  |  |  | (6,765 | ) |  | $ | (1 | ) |  | $ | 11,386,055 |  |  | $ | (7,047,571 | ) |  | $ | 30,215 |  |  | $ | 11,779 |  |  | $ | 4,380,863 |
Redemption of shares |  |  | (6,765 | ) |  |  | (1 | ) |  |  | 6,765 |  |  |  | 1 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (709,707 | ) |  |  | - |  |  |  | 6,613 |  |  |  | (703,094 | )
Foreign currency translation adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,551 | ) |  |  | (302 | ) |  |  | (1,853 | )
Balance as of March 31, 2024 |  |  | 3,848,361 |  |  | $ | 385 |  |  |  | - |  |  | $ | - |  |  | $ | 11,386,055 |  |  | $ | (7,757,278 | ) |  | $ | 28,664 |  |  | $ | 18,090 |  |  | $ | 3,675,916 |
Share based compensation |  |  | 423 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6,667 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6,667 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (442,699 | ) |  |  | - |  |  |  | 10,384 |  |  |  | (432,315 | )
Foreign currency translation adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,777 | ) |  |  | 60 |  |  |  | (1,717 | )
Balance as of June 30, 2024 |  |  | 3,848,784 |  |  | $ | 385 |  |  |  | - |  |  | $ | - |  |  | $ | 11,392,722 |  |  | $ | (8,199,977 | ) |  | $ | 26,887 |  |  | $ | 28,534 |  |  | $ | 3,248,551 |
Share based compensation |  |  | 4,720 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 30,000 |
Roundup of fractional shares upon reverse stock split |  |  | 135,552 |  |  |  | 14 |  |  |  | - |  |  |  | - |  |  |  | (14 | ) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net income (loss) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (509,628 | ) |  |  | - |  |  |  | (14,411 | ) |  |  | (524,039 | )
Foreign currency translation adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 7,224 |  |  |  | 1,889 |  |  |  | 9,113 |
Balance as of September 30, 2024 |  |  | 3,989,056 |  |  | $ | 399 |  |  |  | - |  |  | $ | - |  |  | $ | 11,422,708 |  |  | $ | (8,709,605 | ) |  | $ | 34,111 |  |  | $ | 16,012 |  |  | $ | 2,763,625 |

|  | COMMON STOCK |  |  | TREASURY STOCK |  |  | ADDITIONAL |  |  |  |  |  | ACCUMULATED OTHER |  |  | NON- |  |  | TOTAL |
|  | Number of shares |  |  | Par value |  |  | Number of shares |  |  | Par value |  |  | PAID IN CAPITAL |  |  | ACCUMULATED DEFICIT |  |  | COMPREHENSIVE INCOME |  |  | CONTROLLING INTERESTS |  |  | STOCKHOLDERS’ EQUITY |
Balance as of December 31, 2024 |  |  | 3,989,056 |  |  | $ | 399 |  |  |  | - |  |  |  | - |  |  | $ | 11,422,708 |  |  | $ | (9,518,045 | ) |  | $ | 27,852 |  |  | $ | (3,793 | ) |  | $ | 1,929,121 |
Share based compensation |  |  | 16,325 |  |  |  | 2 |  |  |  | - |  |  |  | - |  |  |  | 29,998 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 30,000 |
Issuance of common stock |  |  | 46,000,000 |  |  |  | 4,600 |  |  |  | - |  |  |  | - |  |  |  | 22,784,368 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 22,788,968 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (698,949 | ) |  |  | - |  |  |  | (13,970 | ) |  |  | (712,919 | )
Foreign currency translation adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (3,209 | ) |  |  | 10 |  |  |  | (3,199 | )
Balance as of March 31, 2025 |  |  | 50,005,381 |  |  | $ | 5,001 |  |  |  | - |  |  | $ | - |  |  | $ | 34,237,074 |  |  | $ | (10,216,994 | ) |  | $ | 24,643 |  |  | $ | (17,753 | ) |  | $ | 24,031,971 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (617,078 | ) |  |  | - |  |  |  | (6,168 | ) |  |  | (623,246 | )
Foreign currency translation adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,394 | ) |  |  | (783 | ) |  |  | (2,177 | )
Balance as of June 30, 2025 |  |  | 50,005,381 |  |  | $ | 5,001 |  |  |  | - |  |  | $ | - |  |  | $ | 34,237,074 |  |  | $ | (10,834,072 | ) |  | $ | 23,249 |  |  | $ | (24,704 | ) |  | $ | 23,406,548 |
Balance |  |  | 50,005,381 |  |  | $ | 5,001 |  |  |  | - |  |  | $ | - |  |  | $ | 34,237,074 |  |  | $ | (10,834,072 | ) |  | $ | 23,249 |  |  | $ | (24,704 | ) |  | $ | 23,406,548 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (586,827 | ) |  |  | - |  |  |  | (8,543 | ) |  |  | (595,370 | )
Net income (loss) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (586,827 | ) |  |  | - |  |  |  | (8,543 | ) |  |  | (595,370 | )
Foreign currency translation adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (11,175 | ) |  |  | (77 | ) |  |  | (11,252 | )
Balance as of September 30, 2025 |  |  | 50,005,381 |  |  | $ | 5,001 |  |  |  | - |  |  | $ | - |  |  | $ | 34,237,074 |  |  | $ | (11,420,899 | ) |  | $ | 12,074 |  |  | $ | (33,324 | ) |  | $ | 22,799,926 |
Balance |  |  | 50,005,381 |  |  | $ | 5,001 |  |  |  | - |  |  | $ | - |  |  | $ | 34,237,074 |  |  | $ | (11,420,899 | ) |  | $ | 12,074 |  |  | $ | (33,324 | ) |  | $ | 22,799,926 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-3

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”)

|  | 2025 |  |  | 2024 |
|  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |  |  |
Net loss |  | $ | (1,931,535 | ) |  | $ | (1,659,449 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation of property and equipment |  |  | 18,512 |  |  |  | 32,411 |
Gain on disposal of property and equipment |  |  | - |  |  |  | (111 | )
Amortization of intangible assets |  |  | 3,503 |  |  |  | 3,611 |
Amortization of finance lease assets |  |  | 32,768 |  |  |  | 18,956 |
Amortization of operating right-of-use assets |  |  | 116,549 |  |  |  | 103,187 |
Unrealized holding loss (gain) on marketable securities |  |  | (3,165 | ) |  |  | 6,642 |
Deferred tax expense |  |  | - |  |  |  | 218 |
Inventory write-off |  |  | 6,961 |  |  |  | - |
Allowance for credit loss |  |  | 11,106 |  |  |  | 28,359 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivables |  |  | 37,284 |  |  |  | 6,353 |
Amount due from related parties |  |  | 141 |  |  |  | 8,858 |
Inventories |  |  | 1,742 |  |  |  | (6,473 | )
Prepaid taxes |  |  | (3,767 | ) |  |  | (8,592 | )
Prepayments and deposits |  |  | (452,749 | ) |  |  | (329,898 | )
Other receivables |  |  | 2,517 |  |  |  | (949 | )
Accounts payable |  |  | (23,328 | ) |  |  | 19,139 |
Accounts payable – related parties |  |  | 2,543 |  |  |  | (10,415 | )
Customer deposits |  |  | (4,211 | ) |  |  | (16,349 | )
Operating lease liabilities |  |  | (117,172 | ) |  |  | (102,605 | )
Other payables and accrued liabilities |  |  | (99,510 | ) |  |  | (179,853 | )
Other payables – related parties |  |  | 1,162 |  |  |  | (7,133 | )
Amount due to directors |  |  | 200,176 |  |  |  | - |
Income tax payable |  |  | (4,601 | ) |  |  | 13,213 |
Net cash used in operating activities |  |  | (2,205,074 | ) |  |  | (2,080,880 | )
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |  |  |  |
Purchase of property and equipment |  |  | (667 | ) |  |  | (48,722 | )
Proceeds from disposal of property and equipment |  |  | - |  |  |  | 111 |
Advances for investment |  |  | (23,000,000 | ) |  |  | - |
Net cash used in investing activities |  |  | (23,000,667 | ) |  |  | (48,611 | )
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |  |  |  |
Proceeds from issuance of common stock |  |  | 23,000,000 |  |  |  | - |
Payment of finance lease liabilities |  |  | (16,710 | ) |  |  | (6,691 | )
Advance from director |  |  | 313,719 |  |  |  | - |
Net cash provided by (used in) financing activities |  |  | 23,297,009 |  |  |  | (6,691 | )
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS |  |  | 2,203 |  |  |  | 22,755 |
DECREASE IN CASH AND CASH EQUIVALENTS |  |  | (1,906,529 | ) |  |  | (2,113,427 | )
CASH AND CASH EQUIVALENTS, beginning of period |  |  | 2,040,243 |  |  |  | 4,832,460 |
CASH AND CASH EQUIVALENTS, end of period |  | $ | 133,714 |  |  | $ | 2,719,033 |
SUPPLEMENTAL CASH FLOWS INFORMATION |  |  |  |  |  |  |  |
Income taxes paid |  | $ | 3,767 |  |  | $ | 10,257 |
Refund of prepaid taxes |  |  | - |  |  |  | 1,665 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-4

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

1. ORGANIZATION AND BUSINESS BACKGROUND

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (“AATP LB”), a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia on August 8, 2003.

AATP LB is an investment holding company with 100% equity interest in Agape ATP International Holding Limited (“AATP HK”), a company incorporated in Hong Kong.

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in ASL, a network marketing entity incorporated in Malaysia.

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn. Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. On July 4, 2024, the entity changed its name to Cedar ATPC Sdn. Bhd. (“CEDAR”).

On November 25, 2024, CEDAR increased its number of ordinary shares to 1,000,000 shares at RM 0.01 per share.

On November 11, 2021, AATP LB formed an entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which AATP LB owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

The Company is positioning itself for sustainable growth by diversifying its operations into the domain of renewable energy. This initiative is founded upon our commitment to environmental responsibility, long-term value creation, and proactive adaptation to global energy trends. On January 3, 2024, the Company formed an equity method investment entity, OIE ATPC Holdings (M) Sdn. Bhd. with Oriental Industries Enterprise (M) Sdn. Bhd. (“OIE”), which the Company and OIE each own 50% of the equity interest. On March 14, 2024, the Company acquired 50% of OIE ATPC Holdings (M) Sdn. Bhd. equity interest from OIE, subsequently the entity becomes a wholly owned subsidiary of the Company. On June 7, 2024, the entity changed its name to ATPC Green Energy Sdn. Bhd (“AGE”).

On September 19, 2024, AGE increased its number of ordinary shares to 1,000,000 shares at RM 0.01 per share.

F-5

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

1. ORGANIZATION AND BUSINESS BACKGROUND (Continued)

On January 8, 2024, AGE formed a wholly own entity, OIE ATPC Exim (M) Sdn. Bhd (“ATPC Exim”). However, the Company had decided not to proceed with the continued development of ATPC Exim. There is no impact to the Group’s operation.

On December 25, 2024, the Company incorporated ATPC Technology Private Limited (“ATPC Tech”) in China, a wholly owned subsidiary in AATP HK to collaborate with local IT expertise to develop comprehensive digital wellness platform that integrates e-commerce, online consultations, chronic disease management, and robust supply chain services catering to ASEAN market.

Details of the Company’s subsidiaries:

SCHEDULE OF SUBSIDIARIES AND ASSOCIATES

|  | Subsidiary company name |  | Place and date of incorporation |  | Particulars of issued capital |  | Principal activities |  | Proportional of ownership interest and voting power held |
1. |  | Agape ATP Corporation |  | Labuan, March 6, 2017 |  | 100 shares of ordinary share of US$1 each |  | Investment holding |  | 100% |
2. |  | Agape ATP International Holding Limited |  | Hong Kong, June 1, 2017 |  | 1,000,000 shares of ordinary share of HK$1 each |  | Wholesale of health and wellness products; and health solution advisory services |  | 100% |
3. |  | Agape Superior Living Sdn. Bhd. |  | Malaysia, August 8, 2003 |  | 9,590,598 shares of ordinary share of RM1 each |  | Health and wellness products and health solution advisory services via network marketing |  | 99.99% |
4. |  | Agape S.E.A. Sdn. Bhd. |  | Malaysia, March 4, 2004 |  | 2 shares of ordinary share of RM1 each |  | VIE of Agape Superior Living Sdn. Bhd. |  | VIE |
5. |  | Cedar ATPC Sdn. Bhd. (formerly known as Wellness ATP International Holdings Sdn. Bhd.) |  | Malaysia, September 11, 2020 |  | 1,000,000 shares of ordinary share of RM0.01 each |  | The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns |  | 100% |
6. |  | DSY Wellness International Sdn Bhd. |  | Malaysia, November 11, 2021 |  | 1,000 shares of ordinary share of RM1 each |  | Provision of complementary health therapies |  | 60% |
7. |  | ATPC Green Energy Sdn. Bhd. (Formerly known as OIE ATPC Holdings (M) Sdn. Bhd.) |  | Malaysia, March 14, 2024 |  | 1,000,000 shares of ordinary share of RM0.01 each |  | Renewable energy |  | 100% |
8. |  | OIE ATPC Exim (M) Sdn. Bhd. |  | Malaysia, March 14, 2024 |  | 1,000 shares of ordinary share of RM1 each |  | Renewable energy |  | 100% |
9. |  | ATPC Technology Private Limited |  | China, December 25, 2024 |  | 50,000 shares of ordinary share of CNY1 each |  | Digital wellness platform |  | 100% |

F-6

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

1. ORGANIZATION AND BUSINESS BACKGROUND (Continued)

Business Overview

The Company is a provider of health and wellness products and advisory services in the Malaysian market. The Company pursue the mission of helping people to create health and wealth by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle. The Company believe the quality of the products coupled with the effectiveness of the distribution network have been the primary reasons for the success and will allow the Company to pursue future business expansion. In order to further the supply chain, on May 8, 2020, the Company acquired 99.99% of Agape Superior Living Sdn Bhd, with the goal of securing an established network marketing sales channel that has been in existence in Malaysia for the past 15 years. On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn. Bhd., a wholly owned subsidiary in Malaysia, with the aim to pursue the business of promoting wellness and wellbeing lifestyle of the community through the provision of services including online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.

ASL offers two series of products: ATP Zeta Health Program and E.A.T.S. The ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians. The Easy and Tasty Series (“E.A.T.S”) is crafted to bring nutritious lifestyle in convenient approach to maintain healthy living.

The establishment of DSY Wellness is a further expansion of the business into the health and wellness industry. Mr. Steve Yap readily owns 33 proprietary formulas for treating non-communicable disease which he has agreed to bring into the company for joint commercialization. Mr. Steve Yap also has existing clients receiving traditional complimentary medicine or “TCM” in Indonesia and China.

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated CEDAR. Upon its establishment, CEDAR started collaborating with ASL to carry out various wellness programs.

AGE delivers innovative solutions for sustainability, energy savings and promoting environmental stewardship to achieve energy efficiency and carbon neutrality for a healthier environment.

ATPC Technology Private Limited (“ATPC Tech”) intend to collaborate with local IT expertise to develop comprehensive digital wellness platform that integrates e-commerce, online consultations, chronic disease management, and robust supply chain services catering to ASEAN market.

F-7

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying interim unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

The interim unaudited financial information as of September 30, 2025 and for the three and nine months ended September 30, 2025 and 2024 have been prepared without audit, pursuant to the rules and regulations of the SEC and pursuant to Regulation S-X. Certain information and footnote disclosures, which are normally included in annual consolidated financial statements prepared in accordance with U. S. GAAP, have been omitted pursuant to those rules and regulations. The interim unaudited financial information should be read in conjunction with the audited financial statements and the notes thereto, included in the Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025.

In the opinion of management, all adjustments (including normal recurring adjustments) necessary to present a fair statement of the Company’s unaudited financial position as of September 30, 2025, its unaudited results of operations for the three and nine months ended September 30, 2025 and 2024, and its unaudited cash flows for the nine months ended September 30, 2025 and 2024, as applicable, have been made. The unaudited interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.

The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its variable interest entity (“VIE”) over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

Going Concern

As disclosed in the Company’s unaudited condensed consolidated financial statements, the Company incurred a net loss of $1,931,535 and $1,659,449, and net cash used in operating activities of $2,205,074 and $2,080,880 for the nine months ended September 30, 2025 and 2024. As of September 30, 2025 and December 31, 2024, the Company had accumulated a deficit of $11,420,899 and $9,518,045.

The Company had current assets of $24,070,306 which comprised $23,000,000 deposit paid to Bi Cheng Investment Management Limited to identify and manage investment opportunities on behalf of the Company. As of the reporting date, the investment has yet to be identified, and the financial return of the investment is uncertain.

These conditions raised substantial doubt about the Company’s ability to continue as a going concern for the next twelve months.

The Company’s liquidity is based on its ability to generate cash from operating activities and obtain financing from investors to fund its general operations and capital expansion needs. The Company’s ability to continue as a going concern is dependent on management’s ability to increase its revenue while controlling operating cost and expense to generate positive operating cash flow and obtain financing from outside sources and invest in new opportunities to generate financial return to the Company.

The Company believes these actions will improve the Company’s financial position, However, there can be no assurance that these plans and arrangements can be successfully executed and the outcome of these plans are uncertain.

Principles of consolidation

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the three and nine months ended September 30, 2025, SEA, the only VIE of the Company has no significant operations.

Use of estimates

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for inventories obsolescence, impairment of long-lived assets, valuation allowance for deferred tax assets, allowance for credit loss, allowance for estimation of coupon redemption and the assumptions used in the valuation of the derivative financial instruments. Actual results could differ from these estimates.

Cash and cash equivalents

Cash and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

F-8

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Accounts receivable, net

Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. The carrying value of accounts receivable is reduced by an allowance that reflects the Company’s best estimate of the amounts that will not be collected. An allowance for credit loss is recorded in the period when a loss is probable based on an assessment of collectivity by reviewing accounts receivable on a collective basis where similar characteristics exist, primarily base on similar business line, service or product offerings and on an individual basis when the Company identifies specific customers with known disputes or collectivity issues. In determining the amount of the allowance for credit loss, the Company considers historical collectivity based on past due status, the age of the accounts receivable balances, credit quality of the Company’s customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect the Company’s ability to collect from customers. Accounts receivable balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of September 30, 2025 and December 31, 2024, $6,559 and $32,857 allowance for credit loss were recorded.

Inventories

Inventories consist of raw materials and finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the three months ended September 30, 2025 and 2024, the Company did not recognize any inventory write-downs nor write-off. For the nine months ended September 30, 2025 and 2024, there were no inventory write-down, however, there were inventory write-off amounted to $6,961 and $0, respectively.

Prepaid taxes

Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax.

Prepayments and deposits, net

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for credit loss after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the allowance policy and update it if necessary. There was $69,683 allowance for credit loss written-off during the three and nine months ended September 30, 2025 and $0 allowance for credit loss written off during three and nine months ended September 30, 2024. There was $0 and $67,768 allowance for credit loss recorded as of September 30, 2025 and December 31, 2024.

F-9

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Property and equipment, net

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT

|  | Useful Life
Computer and office equipment |  | 5-7 years
Furniture & fixtures |  | 6-7 years
Motor vehicle |  | 5 years
Leasehold improvements |  | Shorter of the remaining lease terms or the estimated useful lives

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

Intangible assets, net

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET

Classification |  | Useful Life
Computer software |  | 5 years

Impairment for long-lived assets

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of September 30, 2025 and December 31, 2024, no impairment of long-lived assets was recognized.

Investment in marketable equity securities

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain (loss) on marketable securities” in each reporting period.

Investment in non-marketable equity securities

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Asset and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluated whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (i) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

F-10

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Customer deposits

Customer deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

Revenue recognition

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

The ASU requires the use of a five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

F-11

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Sales of Skin Care, Health and Wellness products

- Performance obligations satisfied at a point in time

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the skin care, health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

Under the Company’s network marketing business, the Company issues product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the Company’s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer deposits will be reversed when the coupons are used. The Company’s coupons have a validity period of between six and twelve months. If the Company’s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.

For the three months ended September 30, 2025 and 2024, the Company recognized $334 and $565, as forfeited coupon income, respectively. For the nine months ended September 30, 2025 and 2024, the Company recognized $4,927 and $2,952, as forfeited coupon income, respectively.

The Company had contracts for the sales of health and wellness products amounting to $5,154 which it is expected to fulfill within 12 months from September 30, 2025.

Sales of products for the provision of complementary health therapies

- Performance obligations satisfied at a point in time

Products for the provision of complementary health therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable diseases.

The Company prescribes the products for complementary health therapies based on health screening test reports and delivers the products to the customers during the consultation session.

For the three months ended September 30, 2025 and 2024, revenues from products for the provision of complementary health therapies were $222,637 and $227,249 respectively. For the nine months ended September 30, 2025 and 2024, revenues from products for the provision of complementary health therapies were $650,834 and $688,415 respectively.

Provision of Health and Wellness services

- Performance obligations satisfied at a point in time

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test. The health screening test is considered as separate performance obligations. The promises to deliver the health screening test report is separately identifiable, which is evidenced by the fact that the Company provides separate services of delivering the health screening test report.

The Company based on the health screening test contracts with customers, establishes the selling price for the health screening test and place order to the health screening center. The Company obtains control of the test report before they are delivered to the customers. The Company analyze the test report, provides consultations to the customers, bundle it with the Company’s products and services depending on the customer’s needs.

The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation session in person.

For the three months ended September 30, 2025 and 2024, revenues from health and wellness services were $38,932 and $56,503 respectively. For the nine months ended September 30, 2025 and 2024, revenues from health and wellness services were $121,451 and $160,694 respectively.

Sales of products and services for the operations in green energy

- Performance obligations satisfied over time

The Company provides products, technical knowledge and solutions for sustainability and energy savings. The Company delivers the products to the customers and enhances the products that the customer controls. The products that the Company creates have no alternative use to the Company. The Company has an enforceable right to receive payment for performance completed to date, the Company recognized revenue based on the percentage of cost incurred.

For the three months ended September 30, 2025 and 2024, revenues from operation in green energy were $1,274 and $0 respectively. For the nine months ended September 30, 2025 and 2024, revenues from operation in green energy were $138,273 and $0 respectively.

F-12

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Disaggregated information of revenues by products are as follows:

SCHEDULE OF DISAGGREGATED INFORMATION OF REVENUES

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | For the three months ended |  |  | For the nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Energized Mineral Concentrate |  | $ | 15,812 |  |  | $ | 1,097 |  |  | $ | 47,633 |  |  | $ | 1,097 |
Ionized Cal-Mag |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 374 |
LIVO 5 |  |  | 207 |  |  |  | 24,103 |  |  |  | 7,849 |  |  |  | 78,478 |
Soy Protein Isolate Powder |  |  | 536 |  |  |  | 2,292 |  |  |  | 1,797 |  |  |  | 8,616 |
Mix Soy Protein Isolate Powder with Black Sesame |  |  | 631 |  |  |  | 1,641 |  |  |  | 2,603 |  |  |  | 6,893 |
Others – Products for the provision of complementary health therapies |  |  | 222,637 |  |  |  | 227,249 |  |  |  | 650,834 |  |  |  | 688,415 |
Skin care and healthcare products |  |  | 90,564 |  |  |  | 18,404 |  |  |  | 154,689 |  |  |  | 18,404 |
Green Energy |  |  | 1,274 |  |  |  | - |  |  |  | 138,273 |  |  |  | - |
Total revenues - products |  |  | 331,661 |  |  |  | 274,786 |  |  |  | 1,003,678 |  |  |  | 802,277 |
Health and Wellness services |  |  | 38,932 |  |  |  | 56,503 |  |  |  | 121,451 |  |  |  | 160,694 |
Total revenues - products and services |  | $ | 370,593 |  |  | $ | 331,289 |  |  | $ | 1,125,129 |  |  | $ | 962,971 |

Cost of revenue

Cost of revenue comprised the purchase cost of manufactured goods for sale to customers and purchase cost of products and services for the provision of complementary health therapies. For the three and nine months ended September 30, 2025, cost of revenue were $131,490 and $520,800, respectively. For the three and nine months ended September 30, 2024, cost of revenue were $147,104 and $381,805.

Shipping and handling

Shipping and handling charges amounted to $1,196 and $817 for the three months ended September 30, 2025 and 2024, respectively. Shipping and handling charges amounted to $3,078 and $2,577 for the nine months ended September 30, 2025 and 2024, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

Advertising costs

Advertising costs amounted to $7,781 and $36,300 for the three and nine months ended September 30, 2025. Advertising costs amounted to $17,250 and $36,945 for the three and nine months ended September 30, 2024. Advertising costs are expensed as incurred and included in selling expenses.

F-13

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Selling expenses

The Company’s selling expenses typically comprise salaries and benefits expenses, credit card processing fees and promotional expenses. Selling expenses amounted to $61,623 and $41,582 for the three months ended September 30, 2025 and 2024, respectively. Selling expenses amounted to $187,214 and $129,938 for the nine months ended September 30, 2025 and 2024, respectively.

Commission expenses

As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $27,386 and $6,894 for the three months ended September 30, 2025 and 2024, respectively. Commission expenses amounted to $51,350 and $23,573 for the nine months ended September 30, 2025 and 2024, respectively.

General and administrative expenses (“G&A expenses”)

The Company’s G&A expenses typically comprise of salaries and benefits expenses, rental expenses, professional expenses, depreciation expenses and allowance for credit loss. G&A expenses amounted to $751,415 and $683,819 for the three months ended September 30, 2025 and 2024, respectively. G&A expenses amounted to $2,324,451 and $2,152,889 for the nine months ended September 30, 2025 and 2024, respectively.

Defined contribution plan

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $26,969 and $57,304 for the three months ended September 30, 2025 and 2024, respectively. Total expenses for the plans were $80,579 and $87,391 for the nine months ended September 30, 2025 and 2024, respectively.

The related contribution plans include:

| - | Social Security Organization (“PERKESO”) – 1.75% based on employee’s monthly salary capped of RM 6,000;
| - | Employees Provident Fund (“EPF”) –based on employee’s monthly salary, 13% for employee earning RM5,000 and below; and 12% for employee earning RM5,001 and above.
| - | Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 6,000;
| - | Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

Income taxes

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled.

F-14

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. No penalties and interest incurred related to underpayment of income taxes for the three and nine months ended September 30, 2025 and 2024.

The Company conducts much of its business activities in Hong Kong, Malaysia and China and is subject to tax in each of these jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

Comprehensive income (loss)

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

Non-controlling interest

Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (3 ordinary shares out of 9,590,599 shares) of the equity interests of ASL held by three individuals. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.

Earnings (Loss) per share

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common stocks (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common stocks that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three and nine months ended September 30, 2025 and 2024, there were no dilutive shares.

F-15

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Foreign currencies translation and transaction

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive loss.

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary in China maintains its books and record in Chinese Yuan (“CNY”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Period-end MYR : US$1 exchange rate |  |  | 4.21 |  |  |  | 4.47 |
Period-end HKD : US$1 exchange rate |  |  | 7.78 |  |  |  | 7.76 |
Period-end CNY : US$1 exchange rate |  |  | 7.12 |  |  |  | 7.30 |

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Period-average MYR : US$1 exchange rate |  |  | 4.22 |  |  |  | 4.35 |  |  |  | 4.30 |  |  |  | 4.61 |
Period-average HKD : US$1 exchange rate |  |  | 7.81 |  |  |  | 7.79 |  |  |  | 7.80 |  |  |  | 7.81 |
Period-average CNY : US$1 exchange rate |  |  | 7.15 |  |  |  | 7.11 |  |  |  | 7.21 |  |  |  | 7.19 |

F-16

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Fair value of financial instruments

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

| ● | Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
| ● | Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
| ● | Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

Leases

The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

F-17

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

Derivative financial instruments

Derivative financial instruments consist of financial instruments that contain a notional amount and one or more underlying variables such as interest rate, security price, variable conversion rate or other variables, require no initial new investment and permit net settlement. The derivative financial instruments may be free-standing or embedded in other financial instruments. The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company based on the terms of the warrant agreement to determine the warrants as equity instruments or derivative liabilities. The Company follows the provision of ASC 815, Derivatives and Hedging for derivative financial instruments that are classified as equity instruments, the contracts are initially measured at fair value and no subsequent measurement is required for equity instruments. The Company uses Black-Scholes Model to calculate the fair value of the warrant.

Recent accounting pronouncements

Recently issued but not yet adopted

In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. The ASU 2023-09 requires companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). The ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU may have on its consolidated financial statements.

The FASB issued ASU 2024-03 and ASU 2025-01 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, and Clarifying the Effective Date” in November 2024 and January 2025 respectively. This new guidance requires disclosures of additional information of the nature of expenses included in the income statement as well as disclosures about specific expense categories in the notes to the financial statements. The requirements of the new guidance are effective for annual periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, which early adoption permitted. This new guidance can be applied either retrospectively to any or all prior periods presented in the consolidated financial statements or prospectively to financial statements issued for reporting period after the effective date of this new guidance. The Company is currently evaluating the effect of adopting this guidance.

In November 2024, the FASB issued ASU 2024-04 “Debt – Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments”. This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The clarification is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effect of adopting of this ASU.

In July 2025, the FASB issued ASU 2025-05 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. This ASU provides a practical expedient that allows companies to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. This ASU is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within annual reporting periods. Early adoption is permitted. The Company is currently evaluating the effect of adopting of this ASU.

In September 2025, the FASB issued ASU 2025-06 “Intangibles – Goodwill and Other-Internal-Use Software (Subtopic 350-40). This ASU updates the accounting for internal-use software by replacing former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software only when management has authorized and committed funding and it is probable that the project will be completed and the software will be used to perform the intended function. It also supersedes website development cost guidance, moving it to ASC 350-40. This ASU is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the effect of adopting of this ASU.

F-18

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”. The ASU 2023-07 is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. The adoption of this accounting standard has no material impact on the consolidated financial statements.

In March 2024, the FASB issued ASU 2024-01 “Compensation – Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards”. The ASU clarify how an entity determines whether a profits interest or similar award is within the scope of Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation, by adding illustrative guidance. The guidance in ASU 2024-01 is effective for annual reporting periods beginning after December 15, 2024, and can be applied either retrospectively to all prior periods presented in the consolidated financial statements or prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. Early adoption is permitted. The adoption of ASU 2024-01 has no material impact on the Company’s consolidated financial statements.

In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements”. The amendments apply to all reporting entities within the scope of the affected accounting guidance, but in most instances the references removed are extraneous and not required to understand or apply the guidance. Generally, the amendments in ASU 2024-02 are not intended to result in significant accounting changes for most entities. The amendments in this update are effective for annual reporting periods beginning after December 15, 2024 and has no significant impact on our financial statements.

3. VARIABLE INTEREST ENTITY (“VIE”)

SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL’s purchases. The income generated was insufficient to finance its activities and 100% of its business is transacted with ASL. Therefore, it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:

| a. | The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
| b. | The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

Accordingly, the accounts of SEA is consolidated in the accompanying financial statements.

F-19

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

3. VARIABLE INTEREST ENTITY (“VIE”) (Continued)

The carrying amount of the VIE’s assets and liabilities were as follows:

SCHEDULE OF VARIABLE INTEREST ENTITY

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Current assets: |  |  |  |  |  |  |  |
Cash |  | $ | 307 |  |  | $ | 1,139 |
Prepayment and deposits |  |  | - |  |  |  | 7 |
Total current assets |  | $ | 307 |  |  | $ | 1,146 |
Current liabilities: |  |  |  |  |  |  |  |
Other payables and accrued liabilities |  |  | 1,282 |  |  |  | 1,478 |
Total current liabilities |  | $ | 1,282 |  |  | $ | 1,478 |
Net deficit |  | $ | (975 | ) |  | $ | (332 | )

The summarized operating results of the VIE’s are as follows:

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Operating revenues |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Gross profit |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Loss from operations |  | $ | (282 | ) |  | $ | (490 | ) |  | $ | (610 | ) |  | $ | (754 | )
Net loss |  | $ | (282 | ) |  | $ | (490 | ) |  | $ | (610 | ) |  | $ | (754 | )

F-20

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

4. CASH AND CASH EQUIVALENTS

As of September 30, 2025 and December 31, 2024 the Company has $133,714 and $2,040,243, respectively, of cash and cash equivalents, which consists of $133,714 and $240,243, respectively, of cash and cash in banks and $0 and $1,800,000, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranged between 2.06% to 2.55% per annum for the three and nine months ended September 30, 2024. As of September 30, 2025 and December 31, 2024, $216 and $1,806,401 of these balances are not covered by deposit insurance, respectively.

5. ACCOUNTS RECEIVABLE, NET

SCHEDULE OF ACCOUNTS RECEIVABLES

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Accounts receivable |  | $ | 13,996 |  |  | $ | 86,508 |
Less: allowance for credit loss |  |  | (6,559 | ) |  |  | (32,857 | )
Total accounts receivable, net |  | $ | 7,437 |  |  | $ | 53,651 |

Movements of allowance for credit loss are as follows:

SCHEDULE OF ALLOWANCE FOR CREDIT LOSSES

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Beginning balance |  | $ | 32,857 |  |  | $ | 542 |
Addition |  |  | 11,106 |  |  |  | 31,614 |
Write off |  |  | (38,779 | ) |  |  | - |
Exchange rate effect |  |  | 1,375 |  |  |  | 701 |
Ending balance |  | $ | 6,559 |  |  | $ | 32,857 |

6. INVENTORIES

Inventories consist of the following:

SCHEDULE OF INVENTORIES

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Finished goods |  |  | 38,834 |  |  |  | 45,355 |
Raw material |  |  | 1,052 |  |  |  | 992 |
Total |  | $ | 39,886 |  |  | $ | 46,347 |
Total inventories |  | $ | 39,886 |  |  | $ | 46,347 |

For the three months ended September 30, 2025 and 2024, there were no inventory write-down nor write-off respectively. For the nine months ended September 30, 2025 and 2024, there were no inventory write-down, however, there were inventory write-off amounted to $6,961 and $0, respectively.

7. PREPAYMENTS AND DEPOSITS, NET

SCHEDULE OF PREPAID EXPENSES AND DEPOSITS

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Prepaid expenses |  | $ | 703,619 |  |  | $ | 522,460 |
Deposit for investment (1) |  |  | 23,000,000 |  |  |  | - |
Deposits to suppliers |  |  | 131,337 |  |  |  | 131,480 |
Subtotal |  |  | 23,834,956 |  |  |  | 653,940 |
Less: allowance for credit loss – Prepaid expenses |  |  | - |  |  |  | (67,768 | )
Total |  | $ | 23,834,956 |  |  | $ | 586,172 |

(1) |  | The Company entered into an entrusted investment agreement with Bi Cheng Investment Management Limited (“Bi Cheng”) on March 11, 2025, whereby Bi Cheng is responsible to identify and manage suitable investment opportunities on behalf of the Company.

Pursuant to the agreement, the Company remitted a deposit of $23,000,000 to Bi Cheng to be applied toward the cost of future investment, upon successful identification and execution of such an opportunity. As of the reporting date, no investment has been finalized and the funds remain unallocated to a specific investee.

The Company continues to monitor the progress of the investment activities and will reclassify the deposit as an investment asset once a definitive transaction has been completed and the associated rights and obligations have been transferred.

Other prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance for credit loss for such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for credit loss after management has determined that the likelihood of collection is not probable.

F-21

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

7. PREPAYMENTS AND DEPOSITS, NET (Continued)

Movements of allowance for credit loss are as follows:

SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Beginning balance |  | $ | 67,768 |  |  | $ | - |
Addition |  |  | - |  |  |  | 67,091 |
Write off |  |  | (69,683 | ) |  |  | - |
Exchange rate effect |  |  | 1,915 |  |  |  | 677 |
Ending balance |  | $ | - |  |  | $ | 67,768 |

8. PROPERTY AND EQUIPMENT, NET

Property and equipment, net consist of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT, NET

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Computer and office equipment |  | $ | 96,981 |  |  | $ | 91,480 |
Furniture & fixtures |  |  | 123,269 |  |  |  | 115,635 |
Motor vehicle |  |  | 22,308 |  |  |  | 21,043 |
Leasehold improvements |  |  | 200,799 |  |  |  | 189,411 |
Subtotal |  |  | 443,357 |  |  |  | 417,569 |
Property plant and equipment, gross |  |  | 443,357 |  |  |  | 417,569 |
Less: accumulated depreciation |  |  | (428,235 | ) |  |  | (386,106 | )
Total property and equipment, net |  | $ | 15,122 |  |  | $ | 31,463 |

Depreciation expense for the three months ended September 30, 2025 and 2024 amounted to $2,036 and $7,083, respectively. Depreciation expense for the nine months ended September 30, 2025 and 2024 amounted to $18,512 and $32,411, respectively.

9. INTANGIBLE ASSETS, NET

Intangible assets, net, consist of the following:

SCHEDULE OF INTANGIBLE ASSETS, NET

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Computer software |  | $ | 57,894 |  |  | $ | 54,611 |
Less: accumulated amortization |  |  | (47,605 | ) |  |  | (41,529 | )
Total intangible assets, net |  | $ | 10,289 |  |  | $ | 13,082 |

Amortization expense for the three months ended September 30, 2025 and 2024 amounted to $1,183 and $1,256, respectively. Amortization expense for the nine months ended September 30, 2025 and 2024 amounted to $3,503 and $3,611, respectively.

F-22

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

10. INVESTMENT IN MARKETABLE SECURITIES

| (i) | On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
| (ii) | On July 30, 2018, the Company disposed 20 shares of common stock in Greenpro Capital Corp. for $125 at a purchase price of $6.2613 per share.
| (iii) | On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.
| (iv) | On July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split of the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022, the Company has an investment of 116,646 common stock of Greenpro Capital Corp. The Company’s investment of 116,646 common stock of Greenpro Capital Corp. was reduced to 11,665 subsequent to the reverse stock split.
| (v) | On November 3, 2020, the Company received dividend of 6,667 shares of common stock in DSwiss, Inc. for $76,671 at fair value of $11.50 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares
| (vi) | On December 9, 2020, the Company received dividend of 16,663 shares of common stock in DSwiss, Inc. for $83,315 at fair value of $5 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares.
| (vii) | On September 27, 2021, the Company received dividend of 11,665 shares of common stock in SEATech Ventures Corp. for $18,874 at fair value of $1.62 per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.

SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Fair value of investment in marketable securities at the beginning of period / year |  | $ | 13,737 |  |  | $ | 20,171 |
Unrealized holding gain (loss) |  |  | 3,165 |  |  |  | (5,018 | )
Transfer to non-marketable securities |  |  | - |  |  |  | (1,500 | )
Exchange rate effect |  |  | (24 | ) |  |  | 84 |
Fair value of investment in marketable securities at the end of period / year |  | $ | 16,878 |  |  | $ | 13,737 |

F-23

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

11. INVESTMENT IN NON-MARKETABLE SECURITIES

| (i) | On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. (a non-marketable security) for $1,500 at purchase price of $0.0001 per share. Phoenix Plus Corp. obtained approval for Depository Trust Company eligibility on April 26, 2022. Since the commencement of trading of common stock of Phoenix Plus Corp. on May 18, 2022, to July 16, 2024 there were only 12 days traded with number of shares of common stock ranging from 100 to 57,500. The Company deems there is an absence of a readily determinable fair value of the common stock of Phoenix Plus Corp. and has continued to value its investment in the company Phoenix Plus Corp. at cost.
| (ii) | On July 2, 2024, the Company purchased 5% of stock or 15,000,000 shares of common stock with a par value of $0.0001 per share of Radiance Holdings Corp. at the consideration of the 15,000,000 shares of Phoenix Plus Corp held by the Company.

SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES

Radiance Holdings Corp. |  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
Radiance Holdings Corp. |  | September 30, 2025 |  |  | December 31, 2024 |
Cost of investment at the beginning of the period / year |  | $ | 1,500 |  |  | $ | - |
Transfer from investment in marketable securities |  |  | - |  |  |  | 1,500 |
Cost of investment at the end of the period / year |  |  | 1,500 |  |  |  | 1,500 |

12. CUSTOMER DEPOSITS

SCHEDULE OF CUSTOMER DEPOSITS

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Customer deposits – Non-Refundable |  | $ | 98,162 |  |  | $ | 94,015 |
Unexpired product coupons |  |  | 342 |  |  |  | 2,961 |
Total |  | $ | 98,504 |  |  | $ | 96,976 |

Customer deposits represent amounts advanced by customers on product orders and unexpired product coupons issued to the Company’s members and distributors of its network marketing business.

13. OTHER PAYABLES AND ACCRUED LIABILITIES

SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Professional fees |  | $ | 137,641 |  |  | $ | 363,762 |
Promotion expenses |  |  | 34,105 |  |  |  | 32,171 |
Payroll |  |  | 21,497 |  |  |  | 4,685 |
Amounts held in eWallets |  |  | 182,074 |  |  |  | 173,995 |
Tax penalty |  |  | 75,000 |  |  |  | 75,000 |
Others |  |  | 149,786 |  |  |  | 62,823 |
Total |  | $ | 600,103 |  |  | $ | 712,436 |

The Company requires all members and distributors of its network marketing business to maintain an electronic wallet (eWallet) account with the Company. The eWallet is primarily for the crediting of any commission payment that falls below RM100 (or $22.20) and for members or distributors without bank account. Commission payment exceeding the RM100 threshold shall only be credited into the member’s or distributor’s bank upon request. The eWallet functionality allows the members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods provided that each of the withdrawal amount exceeds RM100. Amounts held in eWallets are reflected on the balance sheet as a current liability.

F-24

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

14. RELATED PARTY BALANCES AND TRANSACTIONS

Related party balances

SCHEDULE OF RELATED PARTY BALANCES AND TRANSACTIONS

Amount due from related parties

|  |  |  |  |  | As of |
Name of Related Party |  | Relationship |  | Nature |  | September 30, 2025 |  |  | December 31, 2024 |
TH3 Holdings Sdn Bhd (“TH3”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3 |  | Prepayment of IT expenses |  | $ | 2,279 |  |  | $ | 1,582 |
ATPC Lega Global Sdn Bhd (“Lega”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of Lega |  | General expenses payment on behalf |  |  | - |  |  |  | 730 |
Total |  |  |  |  |  | $ | 2,279 |  |  | $ | 2,312 |

Accounts payable – related parties

|  |  |  |  |  | As of |
Name of Related Party |  | Relationship |  | Nature |  | September 30, 2025 |  |  | December 31, 2024 |
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”) |  | The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd |  | Purchases of products for the provision of complementary health therapies |  | $ | 28,400 |  |  | $ | 30,554 |
SY Welltech Sdn Bhd (“Welltech”) (formerly known as DSY Beauty Sdn Bhd) |  | The directors and shareholders of Welltech are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd |  | Purchases of beauty products |  |  | 186 |  |  |  | 71 |
Cedar Wellness Sdn Bhd (“CW”) |  | The directors of CW are also the directors of Cedar ATPC Sdn Bhd |  | Purchase of skin care and healthcare products |  |  | 780 |  |  |  | - |
Institute of Complementary and Traditional Medicine (“ICTM”) |  | Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also the chairman of ICTM |  | Rental of diagnostic & medical equipment |  |  | 5,698 |  |  |  | - |
Total |  |  |  |  |  | $ | 35,064 |  |  | $ | 30,625 |

F-25

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

Related party balances

Other payable - related parties

|  |  |  |  |  | As of |
Name of Related Party |  | Relationship |  | Nature |  | September 30, 2025 |  |  | December 31, 2024 |
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”) |  | The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd |  | Purchase of products for general use |  |  | 143 |  |  |  | 494 |
Cedar Wellness Sdn Bhd (“CW”) |  | The directors of CW are also the directors of Cedar ATPC Sdn Bhd |  | Payment on behalf for selling and event related expenses |  |  | 1,946 |  |  |  | - |
Ms. Low Mui Chin |  | Ms. Low Mui Chin, the director of Cedar ATPC Sdn Bhd |  | Payment on behalf for selling and event related expenses |  |  | 73 |  |  |  | - |
Mr. How Kok Choong |  | Mr. How Kok Choong, the CEO and director of the Company |  | Salary, Commission expense and borrowing from director |  |  | 520,633 |  |  |  | 356 |
Total |  |  |  |  |  | $ | 522,795 |  |  | $ | 850 |

Related party transactions

Purchases

|  |  |  |  |  | For the three months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”) |  | The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd |  | Purchases of products for the provision of complementary health therapies |  | $ | 87,347 |  |  | $ | 79,758 |
SY Welltech Sdn Bhd (“Welltech”) (formerly known as DSY Beauty Sdn Bhd) |  | The directors and shareholders of Welltech are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd |  | Purchases of beauty products |  |  | 238 |  |  |  | 151 |
Institute of Complementary and Traditional Medicine (“ICTM”) |  | Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also the chairman of ICTM |  | Rental of diagnostic & medical equipment |  |  | 5,577 |  |  |  | - |
Cedar Wellness Sdn Bhd (“CW”) |  | The directors of CW are also the directors of Cedar ATPC Sdn Bhd |  | Purchase of skin care and healthcare products |  |  | 13,379 |  |  |  | - |
Total |  |  |  |  |  | $ | 106,541 |  |  | $ | 79,909 |

F-26

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

Related party transactions

Purchases

|  |  |  |  |  | For the nine months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”) |  | The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd |  | Purchases of products for the provision of complementary health therapies |  | $ | 260,973 |  |  | $ | 246,003 |
SY Welltech Sdn Bhd (“Welltech”) (formerly known as DSY Beauty Sdn Bhd) |  | The directors and shareholders of Welltech are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd |  | Purchases of beauty products |  |  | 389 |  |  |  | 17,231 |
Institute of Complementary and Traditional Medicine (“ICTM”) |  | Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also the chairman of ICTM |  | Rental of diagnostic & medical equipment |  |  | 5,577 |  |  |  | - |
Cedar Wellness Sdn Bhd (“CW”) |  | The directors of CW are also the directors of Cedar ATPC Sdn Bhd |  | Purchase of skin care and healthcare products |  |  | 23,472 |  |  |  | - |
Total |  |  |  |  |  | $ | 290,411 |  |  | $ | 263,234 |

Other purchases

|  |  |  |  |  | For the three months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”) |  | The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd |  | Purchase of products for general use |  | $ | 440 |  |  | $ | 900 |
SY Welltech Sdn Bhd (“Welltech”) (formerly known as DSY Beauty Sdn Bhd) |  | The directors and shareholders of Welltech are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd |  | Purchase of products for general use |  |  | - |  |  |  | 134 |
Total |  |  |  |  |  | $ | 440 |  |  | $ | 1,034 |

F-27

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

Related party transactions

Other purchases

|  |  |  |  |  | For the nine months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”) |  | The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd |  | Purchase of products for general use |  | $ | 2,589 |  |  | $ | 2,681 |
SY Welltech Sdn Bhd (“Welltech”) (formerly known as DSY Beauty Sdn Bhd) |  | The directors and shareholders of Welltech are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd |  | Purchase of products for general use |  |  | 1,162 |  |  |  | 2,800 |
Total other purchases |  |  |  |  |  | $ | 3,751 |  |  | $ | 5,481 |

Commission

|  |  |  |  |  | For the three months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
Mr. How Kok Choong |  | Mr. How Kok Choong, the CEO and director of the Company |  | Commission expense |  | $ | 348 |  |  | $ | 550 |
Total commission |  |  |  |  |  | $ | 348 |  |  | $ | 550 |

F-28

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

Related party transactions

Commission

|  |  |  |  |  | For the nine months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
Mr. How Kok Choong |  | Mr. How Kok Choong, the CEO and director of the Company |  | Commission expense |  | $ | 1,114 |  |  | $ | 1,938 |
Total commission |  |  |  |  |  | $ | 1,114 |  |  | $ | 1,938 |

Other income

|  |  |  |  |  | For the three months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
Ando Design Sdn Bhd (“Ando”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of Ando |  | Rental income |  | $ | - |  |  | $ | 652 |
TH3 Holdings Sdn Bhd (“TH3”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3 |  | Rental income |  |  | 209 |  |  |  | 195 |
Total other income |  |  |  |  |  | $ | 209 |  |  | $ | 847 |

Other income

|  |  |  |  |  | For the nine months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
Ando Design Sdn Bhd (“Ando”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of Ando |  | Rental income |  |  | 232 |  |  |  | 1,954 |
TH3 Holdings Sdn Bhd (“TH3”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3 |  | Rental income |  |  | 627 |  |  |  | 586 |
Total other income |  |  |  |  |  | $ | 859 |  |  | $ | 2,540 |

F-29

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

Related party transactions

Other expenses

|  |  |  |  |  | For the three months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
TH3 Holdings Sdn Bhd (“TH3”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3 |  | IT support services fee |  | $ | 14,922 |  |  | $ | 14,976 |
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”) |  | Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC |  | Office rental expense and facilities |  |  | 27,886 |  |  |  | 21,708 |
Cedar Wellness Sdn Bhd (“CW”) |  | The directors and Cedar Wellness Ms. Low Mui Chin & Ms. Low Bee Yin are also the directors of Cedar ATPC Sdn Bhd |  | Selling and event related expenses |  |  | 14,695 |  |  |  | - |
Total other expenses |  |  |  |  |  | $ | 57,503 |  |  | $ | 36,684 |

Other expenses

|  |  |  |  |  | For the nine months ended September 30, |
Name of Related Party |  | Relationship |  | Nature |  | 2025 |  |  | 2024 |
TH3 Holdings Sdn Bhd (“TH3”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3 |  | IT support services fee |  | $ | 45,627 |  |  | $ | 44,429 |
SY Welltech Sdn Bhd (“Welltech”) (formerly known as DSY Beauty Sdn Bhd) |  | The directors and shareholders of Welltech are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd |  | Purchases of products for general use |  |  | - |  |  |  | 5 |
DSY Wellness and Longevity Center Sdn Bhd (“DSYWLC”) |  | Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC |  | Office rental expense |  |  | 83,658 |  |  |  | 37,338 |
Ando Design Sdn Bhd (“Ando”) |  | Mr. How Kok Choong, the CEO and director of the Company is also a director of Ando |  | Office furniture & fittings and improvements |  |  | - |  |  |  | 1,755 |
Cedar Wellness Sdn Bhd (“CW”) |  | The directors and Cedar Wellness Ms. Low Mui Chin & Ms. Low Bee Yin are also the directors of Cedar ATPC Sdn Bhd |  | Selling and event related expenses |  |  | 38,631 |  |  |  | - |
Total other expenses |  |  |  |  |  | $ | 167,916 |  |  | $ | 83,527 |

F-30

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

15. STOCKHOLDERS’ EQUITY

Preferred stock

As of September 30, 2025 and December 31, 2024, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

Common stock

As of September 30, 2025 and December 31, 2024, there were 500,000,000 common stocks authorized; 50,005,381 and 3,989,056 shares issued and outstanding, respectively.

Pursuant to the resolution passed at the board meeting on February 27, 2025, the Company is authorized to issue 46,000,000 shares of common stock at $0.0001 per share. On March 20, 2025, the Company issued 46,000,000 shares of common stock and received net cash proceeds of $23,000,000.

Share-based compensation

The Company has share-based compensation to the executive director. The share-based compensation expense is recorded in general and administrative expenses. The value of the share is $5,000 a month and the number of share to issue is based on the average market price of the month. The Company will issue the share on half yearly basis.

As of September 30, 2025 and December 31, 2024, there were 16,325 and 5,143 shares issued respectively.

Warrants

On October 10, 2023, the Company entered into an underwriting agreement with Network 1 Financial Securities, Inc., as underwriter named thereof, in connection with its initial public offering (“IPO”) of 1,650,000 shares of common stock, par value $0.0001 per share (the “Shares”) at a price of $4.00 per share. The Company issued Representative’s Warrants to purchase up to 115,500 shares of common stock at $4.40 per share, dated October 13, 2023, to Network 1 Financial Securities, Inc. The warrants shall be exercisable at any time, and from time to time, in whole or in part, 180 days after October 13, 2023 (i.e. the date of issuance) and expiring on October 10, 2028.

The warrants are classified as equity instruments, the contracts are initially measured at fair value and no subsequent measurement is need for equity instruments. The Company uses Black-Scholes Model to calculate the fair value of the warrant. As of October 13, 2023 (the “Grant Date”) the warrant was valued at $38,580 with the following assumptions.

SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD

|  | As of |
|  | October 13, 2023 |
Risk-free interest rate |  |  | 4.65 | %
Expected volatility |  |  | 49 | %
Expected life (in years) |  |  | 5 years |
Expected dividend yield |  |  | 0.00 | %
Fair value of warrants |  | $ | 38,580 |

As of September 30, 2025, there were 115,500 warrants outstanding.

F-31

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

16. NON-CONTROLLING INTEREST

The Company’s non-controlling interest consists of the following:

SCHEDULE OF NON CONTROLLING INTEREST

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
DSY Wellness: |  |  |  |  |  |  |  |
Paid-in capital |  | $ | 97 |  |  | $ | 97 |
Retained earnings |  |  | (31,817 | ) |  |  | (3,136 | )
Accumulated other comprehensive income (loss) |  |  | (1,604 | ) |  |  | (754 | )
Noncontrolling interest gross |  |  | (33,324 | ) |  |  | (3,793 | )
ASL |  |  | - |  |  |  | - |
Total |  | $ | (33,324 | ) |  | $ | (3,793 | )

17. INCOME TAXES (EXPENSES) CREDIT

The United States and foreign components of loss before income taxes were comprised of the following:

SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Tax jurisdictions from: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Local – United States |  | $ | (432,436 | ) |  | $ | (302,021 | ) |  | $ | (1,371,440 | ) |  | $ | (1,130,098 | )
Foreign – Malaysia |  |  | (156,532 | ) |  |  | (222,258 | ) |  |  | (558,515 | ) |  |  | (513,397 | )
Foreign – China |  |  | (136 | ) |  |  | - |  |  |  | (341 | ) |  |  | - |
Foreign – Hong Kong |  |  | (5,070 | ) |  |  | (2,635 | ) |  |  | (43 | ) |  |  | (2,151 | )
Foreign – Tax Jurisdictions |  |  | (5,070 | ) |  |  | (2,635 | ) |  |  | (43 | ) |  |  | (2,151 | )
Loss before income tax |  | $ | (594,174 | ) |  | $ | (526,914 | ) |  | $ | (1,930,339 | ) |  | $ | (1,645,646 | )

Income tax (expense) credit consisted of the following:

SCHEDULE OF INCOME TAX EXPENSE

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Current: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
- Local |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | - |
- Foreign |  |  | (1,196 | ) |  |  | 2,875 |  |  |  | (1,196 | ) |  |  | (13,803 | )
Deferred: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
- Local |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
- Foreign |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Income tax (expense) credit |  | $ | (1,196 | ) |  | $ | 2,875 |  |  | $ | (1,196 | ) |  | $ | (13,803 | )

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiaries that operate in various countries: United States, Malaysia (including Labuan), Hong Kong and China that are subject to taxes in the jurisdictions in which they operate, as follows:

F-32

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

17. INCOME TAXES (EXPENSES) CREDIT (Continued)

United States of America

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate tax rate of 21% on its taxable income. Agape ATP Corporation is also subject to controlled foreign corporations Subpart F income (“Subpart F”) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of 21%. In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied.

For the three and nine months ended September 30, 2025 and 2024, the Company’s foreign subsidiaries did not generate any income that are subject to Subpart F tax and GILTI tax.

As of September 30, 2025 and December 31, 2024, the operations in the United States of America incurred approximately $5,170,000 and $3,799,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income or Subpart F and GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of September 30, 2025 and December 31, 2024 were approximately $1,086,000 and $798,000, respectively.

Malaysia

Agape ATP Corporation, Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd., Cedar ATPC Sdn Bhd., DSY Wellness International Sdn. Bhd. ATPC Green Energy Sdn Bhd and OIE ATPC Exim (M) Sdn Bhd. are governed by the income taxes laws of Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 15% for the first RM 150,000 (or approximately $37,500), 17% for the subsequent RM 150,000 to RM 600,000 (or approximately $37,500 to $150,000) and 24% for the remaining balance for nine months ended September 30, 2025 and 2024.

As of September 30, 2025 and December 31, 2024, the operations in Malaysia incurred approximately $4,009,000 and $3,369,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income. Approximately $799,000, $893,000, $1,335,000, $582,000 and $401,000 of the net operating loss carry forwards will expire in 2031, 2032, 2033, 2034 and 2035, respectively, if unutilized. The deferred tax valuation allowance as of September 30, 2025 and December 31, 2024 were approximately $980,000 and $827,000, respectively.

Hong Kong

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.

China

ATPC Technology Private Limited is subject to the Corporate Income Tax governed by the Income Tax Law of the People’s Republic of China with a unified statutory income tax rate of 25%.

F-33

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

17. INCOME TAXES (EXPENSES) CREDIT (Continued)

The following table sets forth the significant components of the aggregate deferred tax assets of the Company:

SCHEDULE OF DEFERRED TAX ASSETS

|  | September 30, 2025 |  |  | December 31, 2024 |
|  | As of |
|  | September 30, 2025 |  |  | December 31, 2024 |
Deferred tax assets: |  |  |  |  |  |  |  |
Net operating loss carry forwards in U.S. |  | $ | 1,085,762 |  |  | $ | 797,759 |
Net operating loss carry forwards in Malaysia |  |  | 980,951 |  |  |  | 824,143 |
Deferred tax liabilities from temporary difference for property and equipment in Malaysia |  |  | (1,138 | ) |  |  | - |
Unabsorbed capital allowance carry forward in Malaysia |  |  | - |  |  |  | 3,245 |
Less: valuation allowance |  |  | (2,065,575 | ) |  |  | (1,625,147 | )
Deferred tax assets, net |  | $ | - |  |  | $ | - |

Uncertain tax positions

The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of September 30, 2025 and December 31, 2024, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur any interest and penalties tax for the three and nine months ended September 30, 2025 and 2024.

18. CONCENTRATIONS OF RISKS

(a) Major customers

For the three months ended September 30, 2025 and 2024, no customer accounted for 10% or more of the Company’s total revenues.

For the nine months ended September 30, 2025, one company accounted for approximately 12.1% of the Company’s total revenues and no customer accounted for 10% or more of the Company’s total revenues for the nine months ended September 30, 2024.

As of September 30, 2025, two individual customers accounted for approximately 23.8% of the Company’s balance of accounts receivable, respectively. As of December 31, 2024, one company accounted for approximately 79.7% of the Company’s balance of accounts receivable.

(b) Major vendors

For the three months ended September 30, 2025, three vendors accounted for approximately 67.0%, 11.6% and 10.1% of the Company’s total purchases, respectively. For the three months ended September 30, 2024, two vendors accounted for approximately 57.3% and 19.0% of the Company’s total purchases, respectively.

For the nine months ended September 30, 2025, three vendors accounted for approximately 51.4%, 26.0% and 10.4% of the Company’s total purchases, respectively. For the nine months ended September 30, 2024, two vendors accounted for approximately 63.4% and 19.9% of the Company’s total purchases, respectively.

CTA Nutriceuticals (Asia) Sdn Bhd, a related company, accounted for approximately 67.0% and 51.4% of the Company’s total purchases for the three and nine months ended September 30, 2025, respectively. For the three and nine months ended September 30, 2024, it accounted for approximately 57.3% and 63.4% of the Company’s total purchases, respectively.

As of September 30, 2025, two vendors accounted for approximately 69.3% and 23.6% of the Company’s total balance of accounts payable, respectively. As of December 31, 2024, three vendors accounted for approximately 44.3%, 31.8% and 22.9% of the Company’s total balance of accounts payable, respectively.

CTA Nutriceuticals (Asia) Sdn Bhd, a related company, accounted for approximately 23.6% and 22.9% of the Company’s total balance of accounts payable as of September 30, 2025 and December 31, 2024, respectively.

F-34

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

18. CONCENTRATIONS OF RISKS (Continued)

(c) Commission Expenses to Sales Distributors and Stockists

One sales distributor accounted for approximately 47.3% of the Company’s commission expense for the three months ended September 30, 2025. No sales distributors accounted for 10% or more of the Company’s commission expense for the three months ended September 30, 2024.

For the nine months ended September 30, 2025, the same sales distributor accounted for approximately 37.6% of the Company’s commission expense. For the nine months ended September 30, 2024, one sales distributor accounted for approximately 20.3% of the Company’s commission expense.

(d) Credit risk

As of September 30, 2025, the Company has entrusted Bi Cheng Investment Limited (“Bi Cheng”), a company incorporated and based in the People’s Republic of China (“PRC”) to manage a significant portion of its liquid assets, totaling approximately $23,000,000. These funds are maintained in accounts controlled by Bi Cheng in the PRC.

The Company is subject to credit risk arising from the possibility that Bi Cheng may fail to fulfill its contractual obligations, including the safekeeping and liquidity of the entrusted funds. In assessing the risk, management considers the financial condition and reputation of Bi Cheng.

While the Company has contractual rights to recover the entrusted funds and conducts periodic monitoring, there can be no assurance that such funds will be fully recoverable in a timely manner due to uncertainties in the legal, regulatory, and foreign exchange frameworks in the PRC. These uncertainties may affect the Company’s ability to access or repatriate the funds, particularly in adverse economic or political conditions.

No allowance for credit loss was recorded as of September 30, 2025, as management believes that the risk of loss is not probable based on current information. However, the Company continues to monitor developments and may revise its assessment should conditions materially change.

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of September 30, 2025, and December 31, 2024, $125,148 and $2,030,048 were deposited with financial institutions, respectively and $216 and $1,806,401 of these balances were not covered by deposit insurance, respectively. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.

Financial instruments that are potentially subject to credit risk consist of accounts receivable, cash, prepayments and deposits and amount due from related parties. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for credit loss based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable. The Company maintains its cash with financial institutions and, as such, believes the credit risk associated with cash deposits is minimal. Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance for credit loss for such advances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance for credit loss is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for credit losses after management has determined that the likelihood of collection is not probable. The amount due from related parties represents payment made by the Company on behalf of related parties, the management considers the credit risk to be low due to the related parties made repayments within reasonable timeframe.

(e) Exchange rate risk

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM, CNY and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

F-35

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

19. LEASE

On July 11, 2024, the Company leased non-commercial vehicle as lessee under finance leases with 5 years lease terms. The Company recognized finance lease liabilities of approximately $72,772, using an effective interest rate of 4.42%, which was determined using the incremental borrowing rate.

SCHEDULE OF LEASE COST

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Components of Leases |  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Operating lease cost |  | $ | 43,134 |  |  | $ | 62,857 |  |  | $ | 124,972 |  |  | $ | 159,720 |
Amortization of finance lease asset |  |  | 11,124 |  |  |  | 11,896 |  |  |  | 32,768 |  |  |  | 18,956 |
Interest on finance lease liabilities |  |  | 2,157 |  |  |  | 2,350 |  |  |  | 6,597 |  |  |  | 4,989 |

Components of leases |  | As of September 30, 2025 |  |  | As of December 31, 2024 |
Weighted average remaining lease term (years) |  |  |  |  |  |  |  |
Operating lease |  |  | 0.76 |  |  |  | 1.49 |
Finance lease |  |  | 3.59 |  |  |  | 4.34 |
Weighted average discount rate |  |  |  |  |  |  |  |
Operating lease |  |  | 5.5 | % |  |  | 5.5 | %
Finance lease |  |  | 6.7 | % |  |  | 6.7 | %

F-36

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

19. LEASE (Continued)

The five-year maturity of the Company’s operating lease liabilities is as follow:

SCHEDULE OF LEASE COMMITMENTS

Twelve Months Ending September 30, |  | Operating lease liabilities |  |  | Finance lease liabilities |
2026 |  | $ | 122,386 |  |  | $ | 31,751 |
2027 |  |  | - |  |  |  | 31,751 |
2028 |  |  | - |  |  |  | 31,751 |
2029 |  |  | - |  |  |  | 53,123 |
Total lease payments |  |  | 122,386 |  |  |  | 148,376 |
Less: interest |  |  | (2,729 | ) |  |  | (20,226 | )
Present value of lease liabilities |  | $ | 119,657 |  |  | $ | 128,150 |

The Company also leases one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of September 30, 2025, the Company’s commitment for minimum lease payment under these operating leases within the next twelve months were $87,634.

Short term lease cost for the three months ended September 30, 2025 and 2024 was $30,540 and $22,218, respectively. For the nine months ended September 30, 2025 and 2024, the short term lease cost was $75,990 and $43,980, respectively.

20. COMMITMENTS AND CONTINGENCIES

The Company has no material commitments or contingencies that are required to be disclosed. The Company has evaluated its obligations and contingencies and determined that no material commitments or contingencies exist at this time.

The Company will continue to monitor and evaluate any potential future commitments or contingencies and will disclose any material items as required.

Legal

The Company is not involved in any material legal proceedings and there are no legal matters that are required to be disclosed.

21. SEGMENT REPORTING

ASC 280 “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Group’s internal organizational management structure as well as information about geographical areas, business segments, and major customers in the financial statements.

Our Chief Executive Officer, who is considered to be our chief operating decision maker, or CODM, reviews financial information presented on an operating segment basis for purposes of making decisions and assessing financial performance.

Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services.

Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services.

Operating results by segment include costs or expenses that are directly attributable to each segment, and costs or expenses that are leveraged across our unified architecture and therefore allocated between the two segments.

F-37

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

21. SEGMENT REPORTING (Continued)

The table below presents details of our reporting segments:

SCHEDULE OF REPORTING SEGMENTS

|  | Skin care, Health and Wellness |  |  | Green Energy |  |  | Unallocated Expenses |  |  | Total |
|  | For the three months ended September 30, 2025 |  |  |  |
|  | Skin care, Health and Wellness |  |  | Green Energy |  |  | Unallocated Expenses |  |  | Total |
Revenues |  | $ | 369,319 |  |  |  | 1,274 |  |  | $ | - |  |  | $ | 370,593 |
Operating loss |  | $ | (155,765 | ) |  |  | (854 | ) |  | $ | (438,751 | ) |  | $ | (595,370 | )
Total assets |  | $ | 566,113 |  |  | $ | 73,559 |  |  | $ | 23,749,672 |  |  | $ | 24,389,344 |

|  | For the three months ended September 30, 2024 |  |  |  |
|  | Skin care, Health and Wellness |  |  | Green Energy |  |  | Unallocated Expenses |  |  | Total |
Revenues |  | $ | 331,289 |  |  |  | - |  |  |  | - |  |  |  | 331,289 |
Operating loss |  | $ | (217,836 | ) |  |  | (599 | ) |  |  | (305,604 | ) |  |  | (524,039 | )
Total assets |  | $ | 979,329 |  |  | $ | 2,423 |  |  | $ | 2,981,942 |  |  | $ | 3,963,694 |

|  | For the nine months ended September 30, 2025 |  |  |  |
|  | Skin care, Health and Wellness |  |  | Green Energy |  |  | Unallocated Expenses |  |  | Total |
Revenues |  | $ | 986,856 |  |  |  | 138,273 |  |  | $ | - |  |  | $ | 1,125,129 |
Operating (loss) gain |  | $ | (556,706 | ) |  |  | 1,009 |  |  | $ | (1,375,838 | ) |  | $ | (1,931,535 | )
Total assets |  | $ | 566,113 |  |  | $ | 73,559 |  |  | $ | 23,749,672 |  |  | $ | 24,389,344 |

|  | For the nine months ended September 30, 2024 |  |  |  |
|  | Skin care, Health and Wellness |  |  | Green Energy |  |  | Unallocated Expenses |  |  | Total |
Revenues |  | $ | 962,971 |  |  | $ | - |  |  | $ | - |  |  | $ | 962,971 |
Operating loss |  | $ | (513,370 | ) |  | $ | (1,745 | ) |  | $ | (1,144,334 | ) |  | $ | (1,659,449 | )
Total assets |  | $ | 979,329 |  |  | $ | 2,423 |  |  | $ | 2,981,942 |  |  | $ | 3,963,694 |

The “Unallocated Expenses” category comprises corporate headquarter operations and one minor business components.

22. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date of issuance of this unaudited condensed consolidated financial statements, and did not identify any events with material financial impact on the Company’s unaudited condensed consolidated financial statements.

F-38

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated March 31, 2025, for the year ended December 31, 2024 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our unaudited condensed consolidated financial statements and the notes to the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q.

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

Company Overview

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (“AATP LB”), a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia on August 8, 2003.

AATP LB is an investment holding company with 100% equity interest in Agape ATP International Holding Limited (“AATP HK”), a company incorporated in Hong Kong.

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., a network marketing entity incorporated in Malaysia.

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn. Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. On July 4, 2024, the entity changed its name to Cedar ATPC Sdn. Bhd. (“CEDAR”).

On November 25, 2024, CEDAR increased its number of ordinary shares to 1,000,000 shares at RM 0.01 per share.

On November 11, 2021, AATP LB formed an entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which AATP LB owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

3

The Company is positioning itself for sustainable growth by diversifying its operations into the domain of renewable energy. This initiative is founded upon our commitment to environmental responsibility, long-term value creation, and proactive adaptation to global energy trends. On January 3, 2024, the Company formed an equity method investment entity, OIE ATPC Holdings (M) Sdn. Bhd. with Oriental Industries Enterprise (M) Sdn. Bhd. (“OIE”), which the Company and OIE each own 50% of the equity interest. On March 14, 2024, the Company acquired 50% of OIE ATPC Holdings (M) Sdn. Bhd. equity interest from OIE, subsequently the entity becomes a wholly owned subsidiary of the Company. On June 7, 2024, the entity changed its name to ATPC Green Energy Sdn. Bhd (“AGE”).

On September 19, 2024, AGE increased its number of ordinary shares to 1,000,000 shares at RM 0.01 per share.

On January 8, 2024, AGE formed a wholly own entity, OIE ATPC Exim (M) Sdn. Bhd (“ATPC Exim”). However, the Company had decided not to proceed with the continued development of ATPC Exim. There is no impact to the Group’s operation.

On December 25, 2024, the Company incorporated ATPC Technology Private Limited (“ATPC Tech”) in China, a wholly owned subsidiary in AATP HK to collaborate with local IT expertise to develop comprehensive digital wellness platform that integrates e-commerce, online consultations, chronic disease management, and robust supply chain services catering to ASEAN market.

Results of Operation

For the three months ended September 30, 2025 and 2024

Revenue

We generated revenue of $370,593, which comprised revenue from the Company’s network marketing business of $17,186 (approximately 4.6% of total revenue); revenue from the Company’s operations in the provision of complementary health therapies of $261,569 (approximately 70.6% of total revenue); $90,564 from skin care and healthcare products (approximately 24.4% of total revenue) and $1,274 from the operation in green energy (approximately 0.4% of total revenue) for the three months ended September 30, 2025 as compared to $331,289, which comprised revenue from the Company’s network marketing business of $29,133 (approximately 8.8% of total revenue); revenue from the Company’s operations in the provision of complementary health therapies of $283,752 (approximately 85.7% of total revenue) and revenue from Company’s operation in wellness and wellbeing lifestyle of $18,404 (approximately 5.5% of total revenue) for the three months ended September 30, 2024.

Revenue from the Company’s network marketing business decreased by $11,947, or approximately 41.0%. Revenue from the Company’s operations in the provision of complementary health therapies decreased by $22,183, or approximately 7.8%. Revenue from skin care and healthcare products increased by $72,160 or approximately 392.1% and revenue of $1,274 was generated from the new operation in green energy. Total revenue increased by $39,304, or approximately 11.9%.

The decrease in revenue from the Company’s network marketing business was due to a strategic shift in focus toward new revenue streams aimed at restoring growth and diversifying income sources. Additionally, revenue from the Company’s operations in the provision of complementary health therapies declined because, in 2025, the Company did not generate any revenue from overseas customers. The increase in revenue from skin care and healthcare products was due to the company’s digital advertisement campaign and marketing activities to promote the skin care and healthcare products.

Cost of Revenue

Cost of revenue for the three months ended September 30, 2025 amounted to $131,490 as compared to $147,104 for the three months ended September 30, 2024, a decrease of $15,614, or approximately 10.6%. The decrease was due to the decrease in revenue in the Company’s network marketing business, the varying gross profit margins in the Company’s operations in the provision of complementary health therapies and the low cost of revenue in the skin care and health care products as compared to the operation in the Company’s network marketing business and the provision of complementary health therapies.

Cost of revenue typically comprise of cost of goods purchased, packing materials and services acquired.

4

Gross Profit

Gross profit for the three months ended September 30, 2025 amounted to $239,103, represented a gross margin of approximately 64.5% as compared to $184,185 for the three months ended September 30, 2024, equivalent to a gross margin of approximately 55.6%. The increase in gross margin was due to higher gross margin contributed by the skin care and health care products as compared to the Company’s network marketing business operations and the provision of complementary health therapies

Operating Expenses

Our operating expenses consist of selling expenses, commission expenses and general and administrative expenses (as defined below). Total operating expenses were $840,424 for the three months ended September 30, 2025, increased by $108,129 or approximately 14.8% from $732,295 for the three months ended September 30, 2024.

Selling expenses

Selling expenses for the three months ended September 30, 2025 amounted to $61,623 as compared to $41,582 for the three months ended September 30, 2024, an increase of $20,041, or approximately 48.2%. The Company’s selling expenses typically comprise of salaries and benefits expenses, credit card processing fees, advertisement and promotional expenses.

Commission expenses

Commission expenses were $27,386 and $6,894 for the three months ended September 30, 2025 and 2024, respectively. The Company pays commission in Company’s network marketing business and the operation in wellness and wellbeing lifestyle. The increase in commission expenses was due to the increase in revenue from the operation in wellness and wellbeing lifestyle.

General and administrative expenses (“G&A Expenses”)

G&A expenses for the three months ended September 30, 2025 amounted to $751,415, as compared to $683,819 for the three months ended September 30, 2024, an increase of $67,596, or approximately 9.9%. The Company’s G&A expenses typically comprise of salaries and benefits expenses, rental expenses, professional expenses, depreciation expenses and other expenses. The increase in G&A expenses was mainly due to the expenses incurred in the operation in wellness and wellbeing lifestyle.

Other Income (Expenses), Net

For the three months ended September 30, 2025, the Company recorded an amount of $7,147 as other income, net, as compared to $21,196 as other income, net, for the three months ended September 30, 2024, represented a decrease of $14,049 in other income, net, or approximately 66.3%.

The other income, net of $7,147 generated during the three months ended September 30, 2025 comprised of foreign currency exchange gain of $7,860, unrealized holding loss on marketable securities of $3,487, other income, net of $2,774. The other income, net of $21,196 generated during the three months ended September 30, 2024 comprised of foreign currency exchange gain of $2,525, unrealized holding loss on marketable securities of $1,176, other income, net of $3,445, gain on disposal of property and equipment of $111 and interest income of $16,291.

Income Tax (Expense) Credit

The Company recorded provision for income taxes of $1,196 and benefit of income taxes of $2,875 for the three months ended September 30, 2025 and 2024, respectively. Both the provision for income taxes as well as the benefit of income taxes were in respect of the Company’s operations in Malaysia.

5

Net Loss

Net loss increased by $71,331 from a net loss of $524,039 for the three months ended September 30, 2024 to a net loss of $595,370 for the three months ended September 30, 2025, mainly due to reasons as discussed above.

For the nine months ended September 30, 2025 and 2024

Revenue

We generated revenue of $1,125,129 which comprised revenue from the Company’s network marketing business of $59,882 (approximately 5.3% of total revenue); and revenue from the Company’s operations in the provision of complementary health therapies of $772,285 (approximately 68.6% of total revenue); $154,689 from skin care and healthcare products (approximately 13.8% of total revenue) and $138,273 from the operation in green energy (approximately 12.3% of total revenue) for the nine months ended September 30, 2025 as compared to $962,971, which comprised revenue from the Company’s network marketing business of $95,458 (approximately 9.9% of total revenue); revenue from the Company’s operations in the provision of complementary health therapies of $849,109 (approximately 88.2% of total revenue) and revenue from Company’s operation in wellness and wellbeing lifestyle of $18,404 (approximately 1.9% of total revenue) for the nine months ended September 30, 2024.

Revenue from the Company’s network marketing business decreased by $35,576, or approximately 37.3%. Revenue from the Company’s operations in the provision of complementary health therapies decreased by $76,824, or approximately 9.0%. Revenue from skin care and healthcare products increased by $136,285 or approximately 740.5% and revenue of $138,273 was generated from the new operation in green energy. Total revenue increased by $162,158, or approximately 16.8%.

The decrease in revenue from the Company’s network marketing business was due to a strategic shift in focus toward new revenue streams aimed at restoring growth and diversifying income sources. Additionally, revenue from the Company’s operations in the provision of complementary health therapies declined because, in 2025, the Company did not generate any revenue from overseas customers. The increase in revenue from skin care and healthcare products was due to the company’s digital advertisement campaign and marketing activities to promote the skin care and healthcare products.

Cost of Revenue

Cost of revenue for the nine months ended September 30, 2025 amounted to $520,800 as compared to $381,805 for the nine months ended September 30, 2024, an increase of $138,995, or approximately 36.4%.

The increase was due to the inventory write off in the Company’s network marketing business; the varying gross profit margins in the Company’s operations in the provision of complementary health therapies; and the cost from the new operation in green energy.

Cost of revenue typically comprise of cost of goods and services purchased, packing materials and services acquired.

Gross Profit

Gross profit for the nine months ended September 30, 2025, amounted to $604,329, represented a gross margin of approximately 53.7% as compared to $581,166 for the nine months ended September 30, 2024, equivalent to a gross margin of approximately 60.4%. The decrease in gross margin was due to the inventory write off in the Company’s network marketing business, the varying type of health therapies offered, gross margin associated with the provision of complementary health therapies and low gross margin in the new operation in green energy.

Operating Expenses

Our operating expenses consist of selling expenses, commission expenses, general and administrative expenses. Total operating expenses were $2,563,015 for the nine months ended September 30, 2025, increased by $256,615 or approximately 11.1% from $2,306,400 for the nine months ended September 30, 2024.

Selling expenses

Selling expenses for the nine months ended September 30, 2025 amounted to $187,214 as compared to $129,938 for the nine months ended September 30, 2024, an increase of $57,276, or approximately 44.1%, mainly due to the increase in advertisement cost and marketing event related expenses. The Company’s selling expenses typically comprise of salaries and benefits expenses, credit card processing fees, advertisement and promotional expenses.

6

Commission expenses

Commission expenses were $51,350 and $23,573 for the nine months ended September 30, 2025 and 2024, respectively, an increase of $27,777, or approximately 117.8%. The Company pays commission in Company’s network marketing business and the operation in wellness and wellbeing lifestyle. The increase in commission expenses was due to the increase in revenue from the operation in wellness and wellbeing lifestyle.

General and administrative expenses

G&A expenses for the nine months ended September 30, 2025 amounted to $2,324,451, as compared to $2,152,889 for the nine months ended September 30, 2024, an increase of $171,562, or approximately 8.0%. The increase in G&A expenses was due to the increase in rental expenses and the operation in wellness and wellbeing lifestyle. The Company’s G&A expenses typically comprise of salaries and benefits expenses, rental expenses, professional expenses, depreciation expenses and other expenses.

Other Income (Expenses), Net

For the nine months ended September 30, 2025, the Company recorded an amount of $28,347 as other income, net, as compared to $79,588 other income, net, for the nine months ended September 30, 2024, represented a decrease of $51,241 in other income, net, or approximately 64.4%.

The other income, net of $28,347 generated during the nine months ended September 30, 2025 comprised foreign currency exchange gain of $6,990, unrealized holding gain on marketable securities of $3,165, other income, net of $14,776, and interest income of $3,416. The other income, net of $79,588 generated during the nine months ended September 30, 2024 comprised foreign currency exchange gain of $1,745, unrealized holding loss on marketable securities of $6,642, other income, net of $25,942, gain on disposal of property and equipment of $111 and interest income of $58,432.

Income Tax (Expense) Credit

The Company recorded provision for income taxes of $1,196 and $13,803 for the nine months ended September 30, 2025 and 2024, respectively. The provision for income taxes were in respect of the Company’s operations in Malaysia.

Net Loss

Net loss increased by $272,086 from net loss of $1,659,449 for the nine months ended September 30, 2024 to net loss of $1,931,535 for the nine months ended September 30, 2025, mainly due to reasons as discussed above.

Liquidity and Capital Resources

As of September 30, 2025, the Company had working capital of $22,585,047 consisting of cash and cash in bank of $133,714 and $0 of time deposit as compared to working capital of $1,656,571 consisted of cash and cash in bank of $240,243 and time deposits of $1,800,000 as of December 31, 2024. The Company had a net loss of $1,931,535 for the nine months ended September 30, 2025 and accumulated deficits of $11,420,899 as of September 30, 2025 as compared to net loss of $2,486,044 for the year ended December 31, 2024 and accumulated deficits of $9,518,045 as of December 31, 2024.

The following summarizes the key components of our cash flows for the nine months ended September 30, 2025 and 2024:

|  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |
Net cash used in operating activities |  | $ | (2,205,074 | ) |  | $ | (2,080,879 | )
Net cash used in investing activities |  |  | (23,000,667 | ) |  |  | (48,611 | )
Net cash provided by (used in) financing activities |  |  | 23,297,009 |  |  |  | (6,691 | )
Effect of exchange rate on cash and cash equivalents |  |  | 2,203 |  |  |  | 22,754 |
Decrease in cash and cash equivalents |  | $ | (1,906,529 | ) |  | $ | (2,113,427 | )

7

Operating activities

Net cash used in operating activities for the nine months ended September 30, 2025 was $2,205,074, comprised of net loss of $1,931,535, unrealized holding gain on marketable securities of $3,165, the increase in prepaid taxes of $3,767, the increase in prepayments and deposits of $452,749, the decrease in account payable (including related parties) of $20,785, the decrease in customer deposits of $4,211, the payment of operating lease liabilities of $117,172, the decrease in other payables (including related parties) and accrued liabilities of $98,348, the decrease of income tax payable of $4,601. The net cash used in operating activities was mainly offset by non-cash depreciation and amortization expense of $22,015, amortization of finance assets of $32,768, amortization of operating right-of-use assets of $116,549, inventory write off of $6,961 and allowance for credit loss $11,106, the decrease in accounts receivables of $37,284, the decrease in other receivables from related parties of $141, the decrease in inventories of $1,742, the decrease in other receivables of $2,517 and the increase in amount due to directors of $200,176.

Net cash used in operating activities for the nine months ended September 30, 2024 was $2,080,879, comprised of net loss of $1,659,449, gain on disposal of office equipment of $111, the increase in inventories of $6,473, the increase in prepaid taxes of $8,592, the increase in prepayments and deposits of $329,898, the increase in other receivables $949, the decrease in customer deposits of $16,349, the payment of operating lease liabilities of $102,605, the decrease in other payables (including related parties) and accrued liabilities of $186,986. The net cash used in operating activities was mainly offset by non-cash depreciation and amortization expense of $36,022, amortization of finance assets of $18,956, amortization of operating right-of-use assets of $103,187, unrealized holding loss on marketable securities of $6,642, deferred tax benefit of $218, allowance for credit loss $28,359, the decrease in accounts receivables of $6,353, the decrease in other receivables (including related parties) of $8,858, the increase in account payable (including related parties) $8,724, and the increase of income tax payable of $13,213.

Investing activities

Net cash used in investing activities for the nine months ended September 30, 2025 was $23,000,667, which was mainly from advances for investment.

Net cash used in investing activities for the nine months ended September 30, 2024 was $48,611, which was due to purchase of property and equipment of $48,722 and proceeds from disposal of office equipment $111.

Financing activities

Net cash provided by financing activities for the nine months ended September 30, 2025 was $23,297,009, consisted of the proceeds from issuance of common stock for $23,000,000, reduction of finance lease liability of $16,710 and advance from director of $313,719.

Net cash used in financing activities for the nine months ended September 30, 2024 was $6,691, which was the reduction of finance lease liability.

Credit Facilities

We do not have any credit facilities or other access to bank credit.

Off-Balance Sheet Arrangements

As of September 30, 2025, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

Critical Accounting Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for inventories obsolescence, impairment of long-lived assets, allowance for deferred tax assets, allowance for credit loss, allowance for estimation of coupon redemption and the assumptions used in the valuation of the derivative financial instruments. Following are the methods and assumptions used in determining our estimates.

8

Estimated allowance for inventories obsolescence

Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the nine months ended September 30, 2025 and 2024, there were no inventory write-down, however, there were $6,961 and $0 inventory write-off respectively.

Impairment of long-lived assets

Operating right-of-use assets and property, plant and equipment are stated at costs less accumulated depreciation and impairment, if any. In determining whether an asset is impaired, the Company has to exercise judgment and make estimation, particularly in assessing: (1) whether an event has occurred or any indicators that may affect the asset value; (2) whether the carrying value of an asset is not recoverable that is its carrying amount exceeds the amount of expected undiscounted future cash flows result from the use of the asset. Once it is established that impairment has occurred, the amount of impairment expense is determined as the difference between the carrying value of the asset and its estimated fair value based on a discounted cash flows approach.

As of September 30, 2025 and December 31, 2024, the carrying amounts of operating right-of-use assets amounted to $119,021 and $224,595, respectively, and property, plant and equipment amounted to $15,122 and $31,463, receptively. No impairment losses on operating right-of-use assets and property, plant and equipment were recognized as of September 30, 2025 and December 31, 2024.

Allowance for deferred tax assets

The Company conducts much of its business activities in Malaysia, Hong Kong and China and is subject to tax in each of these jurisdictions. Significant estimates are required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

Deferred tax assets relating to certain temporary differences and tax losses are recognized as management considers it is more likely than not that future taxable profit will be available against which the temporary differences or tax losses can be utilized. Where the expectation is different from the original estimate, such differences will impact the recognition of deferred tax assets and taxation in the periods in which such estimate is changed.

Allowance for credit loss

The Company estimates and records an allowance for credit loss related to its accounts receivable. Credit losses are determined by Current Estimate of Expected Credit Losses model in accordance with Topic 326 – Financial Instruments – Credit Losses. For accounts receivable, the Company considers the age of the accounts receivable balances, credit quality of the Company’s customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect the Company’s ability to collect from customers. As of September 30, 2025 and December 31, 2024, the Company recognize an allowance for credit loss of $6,559 and $32,857, respectively.

Allowance for estimation of coupon redemption

The Company offers various coupon programs to customers, which result in the potential redemption of coupons against future purchases. The estimation of coupon redemption requires assumptions. This estimate is based on historical redemption patterns, customer behavior trends, and the terms and conditions of the coupon programs. Management considers factors such as the type of coupon, the period of validity that could influence redemption rates. The Company makes estimates about the likelihood and timing of coupon redemptions, which may vary based on changing customer behavior and economic conditions. If the actual redemption rate differs from the estimated rate, it could impact the redemption liability and related expenses in future periods. The allowance for coupon redemption is regularly reviewed and adjusted as more information becomes available to ensure that it reflects the expected redemption accurately.

Assumptions used in the valuation of the derivative financial instruments

The Company issued Representative’s Warrants to purchase up to 115,500 shares of common stock at $4.4 per share, dated October 13, 2023, to Network 1 Financial Securities, Inc. The warrants shall be exercisable at any time, and from time to time, in whole or in part, commencing from October 13, 2023 (i.e. the date of issuance) and expiring on October 10, 2028. The Company used Black-Scholes-Merton Model to estimate the fair value of the Warrants and recognized as equity. No subsequent measurement has been performed as the Warrants are classified as equity.

9

Critical Accounting Policies

Revenue recognition

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

Sales of Skin Care, Health and Wellness products

- Performance obligations satisfied at a point in time

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the skin care, health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

Under the Company’s network marketing business, the Company issues product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the Company’s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer deposits will be reversed when the coupons are used. The Company’s coupons have a validity period of between six and twelve months. If the Company’s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.

Sales of products for the provision of complementary health therapies

- Performance obligations satisfied at a point in time

Products for the provision of complementary health therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable diseases.

The Company based on the health screening test report to prescribe the products for the provision of complementary health therapies, the Company deliver the products to the customers during the consultation session.

Provision of Health and Wellness services

- Performance obligations satisfied at a point in time

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test. The health screening test is considered as separate performance obligations. The promises to deliver the health screening test report is separately identifiable, which is evidenced by the fact that the Company provides separate services of delivering the health screening test report.

The Company based on the health screening test contracts with customers, establishes the selling price for the health screening test and place order to the health screening center. The Company obtains control of the test report before they are delivered to the customers. The Company analyze the test report, provides consultations to the customers, bundle it with the Company’s products and services depending on the customer’s needs.

The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation session in person.

Sales of products and services for the operations in green energy

- Performance obligations satisfied over time

The Company provides products, technical knowledge and solutions for sustainability and energy savings. The Company delivered the products to the customers and enhances the products that the customer controls. The products that the Company created has no alternative use to the Company. The Company has an enforceable right to receive payment for performance completed to date, the Company recognized revenue based on the percentage of cost incurred.

10

Fair value of financial instruments

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

| ● | Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
| ● | Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
| ● | Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

Accounting Standards Adopted in 2025

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”. The ASU 2023-07 is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. The adoption of this accounting standard has no material impact on the consolidated financial statements.

In March 2024, the FASB issued ASU 2024-01 “Compensation – Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards”. The ASU clarify how an entity determines whether a profits interest or similar award is within the scope of Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation, by adding illustrative guidance. The guidance in ASU 2024-01 is effective for annual reporting periods beginning after December 15, 2024, and can be applied either retrospectively to all prior periods presented in the consolidated financial statements or prospectively to profits interest and similar awards granted or modified on or after the date at which the entity first applies the amendments. Early adoption is permitted. The adoption of ASU 2024-01 has no material impact on the Company’s consolidated financial statements.

In March 2024, the FASB issued ASU 2024-02 “Codification Improvements – Amendments to Remove References to the Concepts Statements”. The amendments apply to all reporting entities within the scope of the affected accounting guidance, but in most instances the references removed are extraneous and not required to understand or apply the guidance. Generally, the amendments in ASU 2024-02 are not intended to result in significant accounting changes for most entities. The amendments in this update are effective for annual reporting periods beginning after December 15, 2024 and has no significant impact on our financial statements.

Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued.

In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. The ASU 2023-09 requires companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). The ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU may have on its consolidated financial statements.

The FASB issued ASU 2024-03 and ASU 2025-01 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, and Clarifying the Effective Date” in November 2024 and January 2025 respectively. This new guidance requires disclosures of additional information of the nature of expenses included in the income statement as well as disclosures about specific expense categories in the notes to the financial statements. The requirements of the new guidance are effective for annual periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, which early adoption permitted. This new guidance can be applied either retrospectively to any or all prior periods presented in the consolidated financial statements or prospectively to financial statements issued for reporting period after the effective date of this new guidance. The Company is currently evaluating the effect of adopting this guidance.

In November 2024, the FASB issued ASU 2024-04 “Debt – Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments”. This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The clarification is effective for annual reporting periods beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effect of adopting of this ASU.

In July 2025, the FASB issued ASU 2025-05 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. This ASU provides a practical expedient that allows companies to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. This ASU is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within annual reporting periods. Early adoption is permitted. The Company is currently evaluating the effect of adopting of this ASU.

In September 2025, the FASB issued ASU 2025-06 “Intangibles – Goodwill and Other-Internal-Use Software (Subtopic 350-40). This ASU updates the accounting for internal-use software by replacing former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software only when management has authorized and committed funding and it is probable that the project will be completed and the software will be used to perform the intended function. It also supersedes website development cost guidance, moving it to ASC 350-40. This ASU is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the effect of adopting of this ASU.

Except for the above-mentioned pronouncements, there are no other new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

11

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign exchange risk. Substantially most of our revenues are denominated in the Malaysian Ringgit while most of our expenses are denominated in Malaysian Ringgit, U.S. dollar, Chinese Yuan and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general, our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign exchange rate between U.S. dollar and Malaysian Ringgit; U.S. dollar and Chinese Yuan, and U.S. dollar and Hong Kong Dollar because the value of our business is effectively denominated in Malaysian Ringgit, Chinese Yuan and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.

Credit risk. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for credit loss based upon factors surrounding the credit risk of specific customers, historical trends and other information.

ITEM 4 CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Report, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on the foregoing evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2025, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below.

Internal Control Over Financial Reporting

Our management, including our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s chief executive officer and chief financial officer and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

| ● | Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
| ● | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
| ● | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

12

Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

As of September 30, 2025, our management, including our chief executive officer and chief financial officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on such evaluation, the Company’s management, including our chief executive officer and chief financial officer, concluded that, during the period covered by this Report, internal controls and procedures over financial reporting were not effective. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

Identified Material Weakness

A material weakness in internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management, including our chief executive officer and chief financial officer, identified the following material weaknesses during its assessment of internal controls over financial reporting as of September 30, 2025:

(i) insufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP; (ii) lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures and lack of adequate policies and procedures in internal audit function to ensure that the Company’s policies and procedures have been carried out as planned; and (iii) insufficient procedures and policies were in place to assess the credit risk and capabilities of the third-party manager prior to the investment decision .

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

Management’s Remediation Initiatives

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity and debt transactions.

To further strengthen the Company’s internal controls, we plan to initiate the following measures going forward:

1. | We plan to engage a consulting firm that specializes in compliance and internal controls as a temporary solution to improve the internal control.
2. | Once we hire additional employees, we intend to initiate a comprehensive training program and development plan to provide ongoing company-wide trainings regarding internal control and requirements of U.S. GAAP financial statements and related disclosures, with particular emphasis on our accounting staff.

We anticipate that these initiatives will be at least partially, if not fully, implemented by the mid of fiscal year 2026.

Changes in Internal Control over Financial Reporting:

There were no significant changes in our internal controls over financial reporting that occurred during the period ended September 30, 2025 which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting:

13

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest averse to us.

Item 1A. Risk Factors

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

None.

ITEM 6. Exhibits

Exhibit No. |  | Description
31.1 |  | Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
31.2 |  | Rule 13(a)-14(a)/15(d)-14(a) Certification of principal financial officer*
32.1 |  | Section 1350 Certification of principal executive officer *
32.2 |  | Section 1350 Certification of principal financial officer *
101.INS |  | Inline XBRL Instance Document*
101.SCH |  | Inline XBRL Schema Document*
101.CAL |  | Inline XBRL Calculation Linkbase Document*
101.DEF |  | Inline XBRL Definition Linkbase Document*
101.LAB |  | Inline XBRL Label Linkbase Document*
101.PRE |  | Inline XBRL Presentation Linkbase Document*
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AGAPE ATP CORPORATION
| (Name of Registrant)
Date: November 13, 2025 |  |
| By: | /s/ How Kok Choong
| Title: | Chief Executive Officer, President, Director, Secretary and Treasurer
|  | (Principal Executive Officer and Principal Financial Officer)

15

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AGAPE ATP CORPORATION
| (Name of Registrant)
Date: November 13, 2025 |  |
| By: | /s/ LEE Kam-Fan, Andrew
| Title: | Chief Financial Officer,

16